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Abstract: Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play 
an important role in basic cellular processes and are implicated in the pathogenesis of 
several diseases. Progress in our understanding of the biological functions of PKD has been 
limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 
was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For 
structure-activity analysis purposes, a series of analogs was prepared and their in vitro 
inhibitory potency evaluated.  
Keywords: protein kinase D; small molecule inhibitor; benzothienothiazepinone; 
pyrimidines; CID755673; thiazepinothiophenopyrimidinone 
 
1. Introduction 
Protein Kinase D (PKD) is a member of a novel family of serine/threonine kinases and 
diacylglycerol (DAG) receptors that have emerged as key regulators of many important cellular 
processes. The PKD family is now recognized as a subfamily of the Ca2+/calmodulin-dependent kinase 
superfamily. To date, three isoforms of PKD have been identified: PKD1 (formerly PKCµ) [1,2], 
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PKD2 [3], and PKD3 (formerly PKCν) [4]. All three isoforms share a highly homologous sequence 
and a distinct structure that includes a catalytic domain, a pleckstrin homology (PH) domain, which 
mediates protein-protein interactions and PKD autoinhibition, and an N-terminal cysteine-rich 
DAG/phorbol ester binding domain (C1 domain). Both the activation of PKD and the regulatory 
mechanisms that control PKD activity have been well documented. PKD is activated by DAG-
responsive protein kinase C (PKC) isoforms via transphosphorylation of the conserved Ser744 and 
Ser748 within the activation loop of PKD [5-7]. Subsequent autophosphorylation at multiple sites, 
including Ser916, confers full, sustained activity [8,9]. PKD is also subject to spatial regulation by DAG 
or phorbol esters and, as a result, is capable of shuttling between different subcellular compartments 
[10-12]. Accordingly, this canonical DAG/PKC/PKD pathway is crucial to fundamental PKD function 
in cells. 
As a result of its central position in the signal transduction pathway, it is no surprise that PKD has 
been implicated in a variety of cellular processes, including cell proliferation, cell survival through 
oxidative stress-induced activation of nuclear factor-kappaB (NF-κB) signaling [13-15], gene 
expression by regulation of class IIa histone deacetylases (HDAC) [16-18], protein trafficking [19-21], 
cell motility [22,23], and immune responses [24-26]. These functions of PKD are known to impact 
many aspects of tumor biology, and extensive evidence indicates that PKD expression is dysregulated 
in multiple cancer types [27-30]. PKD also plays an active role in pathological processes such as 
cardiac hypertrophy [31,32], angiogenesis [33,34], and tumor cell proliferation and metastasis [35-37], 
making PKD an attractive therapeutic target for drug development [38]. 
Although extensive analysis of the role of PKD in biological processes has been hampered by the 
lack of both a three-dimensional structure and PKD specificity of early inhibitors (i.e. the isoquinoline 
sulfonamide H89 [39], staurosporine analogs [40,41], and resveratrol [42-44]), more potent and 
selective inhibitors have been reported recently [32,38,45-51]. The first breakthrough in this area came 
in 2008 with the identification and characterization of CID755673 (Figure 1), a potent and PKD-
selective kinase inhibitor [52]. CID755673 was reported to inhibit all PKD isoforms with an IC50 of  
200–300 nM, but showed specificity toward PKD over several related kinases [52]. Interestingly, 
CID755673 was not competitive with ATP for enzyme inhibition, suggesting an alternate binding site 
on the enzyme, which may account for the selectivity for PKD compared to other protein kinases. This 
compound was also shown to effectively block PKD-mediated cell functions as well as the tumor-
promoting functions of PKD in prostate cancer cells [52,53]. Despite the high specificity of 
CID755673 and its potent in vitro inhibition of PKD, its cellular activity was relatively weak  
(EC50 = 11.8 µM) [52,53].  
In addition to CID755673, promising ATP-competitive inhibitors continue to emerge in the 
literature [32,45,46,48-51]. The novel 2,6-naphthyridine 1a (Figure 1) was identified by a high 
throughput screen (HTS) as a dual PKC/PKD inhibitor. Modification of this chemotype led to the 
orally available naphthyridine inhibitors 1b and 1c (Figure 1) [50]. Both 1b and 1c were able to block 
PKD phosphorylation and nuclear export of HDAC in the target tissue in vivo; however, their moderate 
kinase selectivity complicated data interpretation. In an effort to reduce the off-target effects and 
improve PKD selectivity, a series of amidobipyridyl-based analogs was generated [51]. From this 
series, BPKDi (Figure 1) was identified as a potent and selective inhibitor of all three isoforms of PKD 
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with single digit nanomolar IC50 values and improved selectivity relative to 1b [32,51]. Furthermore, 
BPKDi caused substantial inhibition of PKD1 signal-dependent phosphorylation and increased nuclear 
retention of class HDAC4 and HDAC5 in cardiomyocytes [32].  
Figure 1. Recent PKD inhibitors reported in the research and patent literature. 
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Another pan-PKD inhibitor, CRT0066101 (Figure 1), was also reported to inhibit all isoforms of 
PKD with single-digit nanomolar IC50s. CRT0066101 was shown to block cell proliferation, induce 
apoptosis, and reduce the viability of pancreatic cancer cells both in vitro and in vivo. As with the 
aforementioned ATP-competitive inhibitors, the most attractive features of CRT0066101 are its 
reported orally availability and efficacy in vivo [46,48]. Lastly, preliminary studies of the structure-
activity relationships (SAR) of a novel 3,5-diarylazole 2a (Figure 1), which was identified in a HTS as 
a moderately potent kinase inhibitor, led to a series of promising benzamide analogs [49]. One analog 
in particular, 2b (Figure 1), was found to inhibit all PKD isoforms with low nanomolar IC50s, while 
showing a 9- and 3-fold preference for PKD1 versus PKD2 and PKD3, respectively. Notably, 2b 
shows high selectivity for PKD against a panel of other kinases, and pharmacokinetic studies in rats 
indicate that compound 2b is orally available [49].  
While all of these ATP-competitive, orally available PKD inhibitors represent valuable tools for 
further study of PKD signaling, their substantial off-target activity may likely be due to the high 
sequence homology near the hinge-binding regions of PKCs and PKDs. Recent evidence suggests 
additional targets of CID755673 [54], but as this lead structure is not competitive with ATP for PKD 
inhibition, it can provide an orthogonal approach to gain further understanding of the structure and 
function of PKD. In an effort to enhance the selectivity and potency for potential in vivo applications, 
small molecule analogs of CID755673 were generated by modification of the core structure as well as 
the side chains. We describe herein the complete SAR conducted thus far, which led to the discovery of 
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a novel benzothienothiazepinone series. The improved PKD1 inhibitory activity of some of these 
analogs has already been highlighted in previous communications [53,55].  
2. Results and Discussion 
2.1. First generation SAR 
Our investigations began with the chromenopyridine-based CID797718, a by-product of the 
synthesis of the parental compound, CID755673 (Table 1). This compound was 10x less potent at 
PKD1 inhibition than CID755673. Efforts to improve the activity of CID797718 by substitution of the 
phenolic hydroxyl group (Table 1, entries 1-3), N-alkylation (Table 1, entry 4), and ortho-halogenation 
(Table 1, entry 5) resulted in a complete loss of PKD1 activity. Consequently, the chromenopyridine 
scaffold was abandoned.  
Table 1. Chemical structures and PKD1 inhibitory activities of CID797718 and its analogs. 
O
N
R5
O
R2
R1
 
Entry Compound 
Structure  IC50 
R1 R2 R5  IMAP-FP PKD1 (µM)a 
Radiometric PKD1 
(µM)b 
1 CID797718 H OH H  13.7 ± 0.42 (n = 3) 2.34 ± 0.16 (n = 3) 
2 kb-NB77-83 H OAllyl H  not inhibitory n.d. 
3 kb-NB77-78 H OTBS H  not inhibitory n.d. 
4 kb-NB77-91 H OH Cbz  not inhibitory n.d. 
5 kb-NB96-47-1 Cl OH H  not inhibitory n.d. 
a
 PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence 
Polarization (FP) assay as previously described [52]. Each IC50 was calculated as the mean ± SEM 
of at least three independent experiments with triplicate determinations at each concentration in 
each experiment; n = number of independent experiments. b PKD1 IC50 was determined using a 
radiometric kinase activity assay as previously described [52]. Each IC50 was calculated as the 
mean ± SEM of at least three independent experiments with triplicate determinations at each 
concentration in each experiment; n = number of independent experiments. 
 
Modifications to the benzofuroazepinone scaffold present in CID755673 proved to be more 
rewarding. The initial SAR analysis included modifications of the azepinone ring, substitution at the 
phenol and amide groups, and functionalization across the aryl moiety (Table 2). Changing the 
azepinone to either a 6- or 8-membered heterocycle resulted in a reduced inhibitory activity towards 
PKD1 (Table 2, entries 2–5). Substitutions of the phenolic hydroxyl group were not well tolerated 
either. Although both the methoxy and allyloxy substituents at that site showed moderate inhibitory 
activity towards PKD1 (Table 2, entries 6 and 7), the acetoxy and siloxy groups (Table 2, entries 8 and 
9) showed poor inhibition and complete loss in activity, respectively. These results indicate that the 
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aryl binding pocket of the protein may be restrictive in terms of both the size and the polarity of the 
aryl substituents. Similarly, alkylation/acylation of the amide or bioisosteric replacement with a 
dihydroimidazole resulted in weak or no PKD1 inhibition (Table 2, entries 10–14). These observations 
suggest that the amide functionality may provide crucial H-bonding interactions in the azepinone 
binding pocket that are required for optimal inhibitor-enzyme interactions. 
Table 2. Chemical structure and PKD1 inhibitory activity of CID755673 and its analogs. 
O
NR2
O
R5
n
 
Entry Compound 
Structure  IC50 
R2 R5 n  IMAP-FP PKD1 (µM)a 
Radiometric 
PKD1 (µM)b 
Cellular PKD1 
(µM)c 
1 CID755673 OH H 1  0.64 ± 0.03 (n = 3) 0.18 ± 0.02 (n = 5) 11.8 ± 4.0 (n = 3) 
2 kb-NB123-23A OH H 0  12.6 ± 1.3 (n = 3) 1.41 (n = 1) n.d. 
3 kb-NB123-32 OMe H 0  >100 n.d. n.d. 
4 kb-NB96-53 OH H 2  8.3 ± 0.6 (n = 3) 1.03 (n = 1) n.d. 
5 kb-NB96-59 OMe H 2  >100 n.d. n.d. 
6 kb-NB77-56 OMe H 1  2.40 ± 0.14 (n = 3) 2.39 (n = 1) n.d. 
7 kb-NB77-84 OAllyl H 1  2.6 ± 0.2 (n = 3) 1.23 (n = 1) n.d. 
8 kb-NB123-36 OAc H 1  84.89 ± 3.21 (n = 3) n.d. n.d. 
9 kb-NB77-77 OTBS H 1  not inhibitory n.d. n.d. 
10 kb-NB123-37 OMe Me 0  not inhibitory n.d. n.d. 
11 kb-NB142-25 OH Me 1  n.d. 4.0 ± 1.1 (n = 2) n.d. 
12 kb-NB96-04 OMe Me 1  >100 n.d. n.d. 
13 kb-NB123-45-1 OAc Ac 1  not inhibitory n.d. n.d. 
14 kb-NB165-15 
O
NHO
N
 
 n.d. not inhibitory n.d. 
a
 PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence 
Polarization (FP) assay as previously described [52]. Each IC50 was calculated as the mean ± SEM 
of at least three independent experiments with triplicate determinations at each concentration in 
each experiment; n = number of independent experiments. b PKD1 IC50 was determined using a 
radiometric kinase activity assay as previously described [52]. Each IC50 was calculated as the 
mean ± SEM with triplicate determinations at each concentration in each experiment; n = number 
of independent experiments. c Cellular IC50 was determined by densitometry analysis of Western 
blotting data for PKD1 autophosphorylation at S916 in LNCaP cells as previously described [53]. 
Each IC50 was calculated as the mean ± SEM of at least two independent experiments; n = number 
of independent experiments. 
 
Based on these results, subsequent synthetic analogs were biased to contain key features of the 
pharmacophore, i.e., the 7-membered ring azepine, the monosubstituted lactam, and a small R2 
substituent (Table 3). Derivatives bearing either a Cl or F atom at the R1 position retained activity 
against PKD1, but did not show improved potency relative to CID755673 (Table 3, entries 1 and 2). In 
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contrast, introduction of a Cl atom at either the R3 position, or both the R1 and R3 positions, provided 
inactive compounds (Table 3, entries 4 and 5). Interestingly, allyl and propenyl groups were well 
tolerated in this region, despite the aforementioned putative size restrictions of the aryl binding region 
(Table 3, entries 6 and 7). The inhibitory activity of these analogs also provides further support for a 
relatively hydrophobic aryl binding pocket. Finally, all modifications of the azepinone moiety at the 5 
position (Z) yielded analogs with reduced inhibitory activity (Table 3, entries 8–12).  
Table 3. Chemical structures and PKD1 inhibitory activities of CID755673 analogs. 
O
NH
Z
R2
O
R1
R3
 
Entry Compound 
Structure  IC50 
Z R1 R2 R3  IMAP-FP PKD1 (µM)a Radiometric 
PKD1 (µM)b 
1 kb-NB77-88 CH2 Cl OH H  1.4 ± 0.1 (n = 3) 0.89 (n = 1) 
2 kb-NB96-21 CH2 F OH H  1.3 ± 0.05 (n = 3) 0.24 (n = 1) 
3 kb-NB96-50 CH2 Cl OAllyl H  not inhibitory n.d. 
4 kb-NB96-47-5 CH2 H OH Cl  >100 n.d. 
5 kb-NB96-43 CH2 Cl OH Cl  not inhibitory n.d. 
6 kb-NB96-02 CH2 Allyl OH H  2.4 ± 0.3 (n = 3) 1.58 (n = 1) 
7 kb-NB96-30 CH2 Propenyl OH H  1.0 ± 0.1 (n = 3) 0.24 (n = 1) 
8 kb-NB123-63 C=O H OH H  14.9 ± 1.2 (n = 3) 0.85 ± 0.11 (n = 2) 
9 kb-NB123-89 CHOH H OH H  24.09 ± 0.71 (n = 3) 1.23 ± 0.21 (n = 2) 
10 kb-NB142-05 C=NNHPh H OH H  21.70 ± 0.52 (n = 3) 1.13 (n = 1) 
11 kb-NB142-11 C=NNHTs H OH H  38.21 ± 1.17 (n = 3) n.d. 
12 kb-NB142-10 C=NOBn H OH H  not inhibitory n.d. 
a
 PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence 
Polarization (FP) assay as previously described [52]. Each IC50 was calculated as the mean ± SEM 
of at least three independent experiments with triplicate determinations at each concentration in 
each experiment; n = number of independent experiments. b PKD1 IC50 was determined using a 
radiometric kinase activity assay as previously described [52]. Each IC50 was calculated as the 
mean ± SEM with triplicate determinations at each concentration in each experiment; n = number 
of independent experiments.  
 
We next sought to investigate the replacement of the benzofuran core by a β-carboline skeleton 
(Table 4). Compound kb-NB123-57 (Table 4, entry 2), which retains all functionality of CID755673 
except for the benzofuran oxygen being replaced with a nitrogen atom, exhibited comparable activity 
toward PKD1; however, there was no significant cellular activity. Variation of either the phenolic 
hydroxyl group or the lactam ring size in the β-carboline series did not provide any enhancement in 
activity (Table 4), and in cases where R2 was replaced with O-benzyl (Table 4, entries 3 and 4) or N-
acyl (Table 4, entries 7 and 8), all inhibitory activity was lost. These modifications, accordingly, 
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confirm that the 7-membered azepinone represents an optimal size and that the binding pocket of the 
protein is sterically demanding at the aryl binding region. 
Table 4. Chemical structure and PKD1 inhibitory activity of the β-carboline analogs. 
N
H
NHR2
O
n
 
Entry Compound 
Structure  IC50 
R2 n  IMAP-FP PKD1 (µM)a 
Radiometric PKD1 
(µM)b 
Cellular PKD1 
(µM)c 
1 kb-NB123-59 OH 0  19.4 ± 1.4 (n = 3) 1.57 ± 0.20 (n = 2) n.d. 
2 kb-NB123-57 OH 1  2.14 ± 0.12 (n = 3) 0.13 ± 0.01 (n = 3) >50 (n = 3) 
3 kb-NB123-52 OBn 0  not inhibitory n.d. n.d. 
4 kb-NB123-53 OBn 1  not inhibitory n.d. n.d. 
5 kb-NB142-08 NH2 0  74.4 ± 2.2 (n = 3) 15.74 ± 0.19 (n = 2)  n.d. 
6 kb-NB142-01 NH2 1  47.1 ± 2.5 (n = 3) 9.68 ± 1.01 (n = 2) n.d. 
7 kb-NB123-93 NHAc 0  not inhibitory n.d. n.d. 
8 kb-NB123-94 NHAc 1  not inhibitory n.d. n.d. 
a
 PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence 
Polarization (FP) assay as previously described [52]. Each IC50 was calculated as the mean ± SEM 
of at least three independent experiments with triplicate determinations at each concentration in 
each experiment; n = number of independent experiments. b PKD1 IC50 was determined using a 
radiometric kinase activity assay as previously described [52]. Each IC50 was calculated as the 
mean ± SEM of at least two independent experiments with triplicate determinations at each 
concentration in each experiment; n = number of independent experiments. c Cellular IC50 was 
determined by densitometry analysis of Western blotting data for PKD1 autophosphorylation at 
S916 in LNCaP cells as previously described [53]. Each IC50 was calculated as the mean ± SEM of 
at least three independent experiments; n = number of independent experiments. 
 
In the next SAR iteration, the benzofuran was replaced with a benzothiophene while the azepine 
was replaced by a thiazepine ring. Gratifyingly, both the benzothienothiazepinone kb-NB142-70 and 
the methoxy analog kb-NB165-09 showed a significance increase in potency toward PKD1, with IC50 
values of 28.3 nM and 82.5 nM, respectively (Table 5, entries 2 and 3). This increased potency was 
further confirmed in cell-based assays, for which the cellular EC50 was lowered ca. 5-fold from  
11.8 µM by CID755673 to 2.2 µM and 3.1 µM by kb-NB142-70 and kb-NB165-09, respectively. The 
remarkable activity of the methyl ether compared to the phenol indicates that a hydrogen bond donor at 
this position is not critical for activity. The lack of activity of the O-benzyl derivative for this series of 
analogs provides additional support for a sterically demanding aryl binding pocket.  
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Table 5. Chemical structures and PKD1 inhibitory activities of benzothienothiazepinone analogs. 
S
NH
S
R2
O
 
Entry Compound 
Structure  IC50 
R2  IMAP-FP PKD1 (µM)a 
Radiometric PKD1 
(µM)b 
cellular PKD1 
(µM)c 
1 kb-NB123-66 OBn  not inhibitory n.d. n.d. 
2 kb-NB142-70 OH  0.71 ± 0.02 (n = 3) 0.028 ± 0.002 (n = 3) 2.22 ± 0.59 (n = 3) 
3 kb-NB165-09 OMe  n.d. 0.08 ± 0.01 (n = 4) 3.13 ± 0.54 (n = 3) 
a
 PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence 
Polarization (FP) assay as previously described [52]. Each IC50 was calculated as the mean ± SEM 
of at least three independent experiments with triplicate determinations at each concentration in 
each experiment; n = number of independent experiments. b PKD1 IC50 was determined using a 
radiometric kinase activity assay as previously described [52]. Each IC50 was calculated as the 
mean ± SEM of at least three independent experiments with triplicate determinations at each 
concentration in each experiment; n = number of independent experiments. c Cellular IC50 was 
determined by densitometry analysis of Western blotting data for PKD1 autophosphorylation at 
S916 in LNCaP cells as previously described [53]. Each IC50 was calculated as the mean ± SEM of 
at least three independent experiments; n = number of independent experiments. 
2.2. Second generation SAR 
The previous screening cycles led to the discovery of the benzothienothiazepinone kb-NB142-70 as 
the most potent analog with an IC50 of 28.3 nM, which was an almost 7-fold improvement in potency 
over the parent compound, CID755673. Furthermore, we had gained considerable understanding of the 
SAR of the tricyclic inhibitor scaffold. Accordingly, we updated our pharmacophore model based on 
the structure of kb-NB142-70, and devised 4 major structural zones (Figure 2): zone I (aryl moiety), 
zone II (thiophene), zone III (thiazepinone), and zone IV (amide function). Each of these zones was 
subjected to selected structural modifications in order to elucidate essential activity relationships. 
In zone I, the phenolic substituent and the substitution across the aryl moiety were modified (Table 6). 
Most of the zone I analogs were less active than the lead, kb-NB142-70. Specifically, substitutions at 
R4 were detrimental to in vitro activity (Table 6, entries 7–9), at least when R2 = H. In contrast, 
halogenation at R1 (Table 6, entries 5 and 6) and replacement of the phenolic hydroxy group with 
amine variants (Table 6, entries 1–4) were surprisingly well tolerated. Notably, the azide analog, 
mcf292-08, maintained a high inhibitory activity both in vitro and in cells, with IC50 values of 74.9 nM 
and 2.2 µM, respectively, thereby providing further support for the limited significance of a hydrogen 
bond donor at this position. The ortho-iodinated analog, kb-NB165-31, was also a potent inhibitor 
with an IC50 value of 114 nM; however, its cellular activity was 4-fold lower than that of kb-NB142-
70. Masking the hydroxyl group of the lead kb-NB142-70 was only slightly detrimental to the in vitro 
biological activity, as revealed by the methoxy analog kb-NB165-09. Moreover, preliminary results 
from an animal model suggest the glucuronidation of kb-NB142-70 at the phenolic position to be a 
major metabolic pathway.  
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Figure 2. Major structural zones for SAR analysis based on kb-NB142-70. 
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Table 6. Chemical structures and PKD1 inhibitory activities of analogs with zone I modifications. 
S
NH
S
R2
O
R1
R4
 
Entry Compound 
Structure IC50 
R1 R2 R4 % PKD1 activity 
at 1 µM 
Radiometric 
PKD1 (µM)a 
Cellular PKD1 
(µM)b 
1 mcf292-03 H NH2 H 74.4 ± 1.1 (n = 2) 3.17 (n = 1) n.d. 
2 mcf292-08 H N3 H n.d. 0.08 ± 0.01 (n = 5) 2.17 ± 0.22 (n = 3) 
3 mcf292-05 H N=C=S H n.d. 2.77 (n = 1) n.d. 
4 mcf292-09 H NHCOCH2Cl H n.d. 1.50 (n = 1) n.d. 
5 kb-NB165-31 I OH H 13.6 (n = 1) 0.11 ± 0.02 (n = 3) 8.6 ± 2.0 (n = 3) 
6 kb-NB184-52 Br OH H 12.7 ± 0.2 (n = 2) 0.048 (n = 1) n.d. 
7 kb-NB184-38 H H OBn 98.6 ± 4.1 (n = 2) n.d. n.d. 
8 kb-NB184-40 H H OH 99 ± 11 (n = 2) n.d. n.d. 
9 kb-NB184-44 H H OMe 77.5 ± 3.6 (n = 2) n.d. n.d. 
a
 PKD1 IC50 was determined using a radiometric kinase activity assay as previously described [52]. 
Each IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration 
in each experiment; n = number of independent experiments. b Cellular IC50 was determined by 
densitometry analysis of Western blotting data for PKD1 autophosphorylation at S916 in LNCaP 
cells as previously described [53]. Each IC50 was calculated as the mean ± SEM of at least three 
independent experiments; n = number of independent experiments. 
 
Therefore, the methoxy analogs were systematically developed in addition to the corresponding 
phenols in order to potentially circumvent a rapid excretion scenario in vivo. As part of our zone II and 
III modifications, the oxidation state of the benzothiophene sulfur atom, the size of the thiazepinone 
ring, and the oxidation and substitution of the thiazepinone ring sulfur atom were explored (Table 7). 
Sulfur oxidations in zones II and III provided analogs with reduced activity (Table 7, entries 1–3), 
while increasing the thiazepinone ring size by the addition of a methylene group had only minor effects 
on PKD1 inhibition for both the hydroxy and methoxy analogs (Table 7, entries 5 and 6). Additionally, 
the replacement of the thiazepinone ring sulfur atom with an oxygen resulted in a loss of inhibitory 
activity (Table 7, entries 7 and 8), suggesting high hydrophobicity and polarizability to be preferred in 
zone III. Attempts to exchange the thiazepinone ring sulfur atom with a nitrogen atom were met with 
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preparative difficulties. The desired diazepinone ring could not be formed, and, as a result, an acyclic 
precursor was submitted for testing (Table 7, entry 9). The lack of activity of this analog suggests that 
the zone III binding pocket may require the rigidity of a ring system for optimal binding interactions.  
Table 7. Chemical structures and PKD1 inhibitory activities of zone II and III modifications. 
Y
NH
Z
R2
O
n
 
Entry Compound 
Structure  IC50 
Y Z R2 n  % PKD1 activity at 1 µM 
Radiometric PKD1 
(µM)a 
Cellular PKD1 
(µM)b 
1 kb-NB184-22 S=O S OH 1  66.5 ± 6.1 (n = 2) n.d. n.d. 
2 kb-NB184-25 S=O S OMe 1  50.4 ± 2.3 (n = 2) 1.08 (n = 1) n.d. 
3 kb-NB184-45 S S=O OMe 1  97 ± 16 (n = 2) n.d. n.d. 
4 kb-NB165-89 S S OBn 2  84.3 (n = 1) 21.7 (n = 1) n.d. 
5 kb-NB165-92 S S OH 2  16.7 (n = 1) 0.11 ± 0.01 (n = 3) 2.56 ± 0.66 (n = 2) 
6 kb-NB184-02 S S OMe 2  29.5 (n = 1) 0.19 ± 0.03 (n = 3) 18.6 ± 2.0 (n = 3) 
7 kb-NB184-36 S O OBn 2  83.3 ± 3.8 (n = 2) n.d. n.d. 
8 kb-NB184-57 S O OMe 2  62.0 ± 3.5 (n = 2) n.d. n.d. 
9 kb-NB184-80 
S
HN
O
OH
CO2Me
 
 91.3 ± 1.5 (n = 2) not inhibitory n.d. 
a
 PKD1 IC50 was determined using a radiometric kinase activity assay as previously described [52]. 
Each IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration 
in each experiment; n = number of independent experiments. b Cellular IC50 was determined by 
densitometry analysis of Western blotting data for PKD1 autophosphorylation at S916 in LNCaP 
cells as previously described [53]. Each IC50 was calculated as the mean ± SEM of at least two 
independent experiments; n = number of independent experiments. 
 
Furthermore, modifications to zone IV, which included functional group interconversions and 
replacement of the amide moiety, did not enhance the inhibitory activity (Table 8). These results 
suggest that the unique hydrogen bond donor-acceptor capability of the amide is critical for protein 
interactions within the zone IV binding pocket.  
The results from both the initial and the second generation SAR firmly established that the 
benzothienothiazepinones displayed superior PKD1 inhibition compared to the benzofuroazepinones. 
The most potent analog, kb-NB142-70, inhibited PKD1 with an IC50 of 28 nM, which is nearly a 7-
fold improvement in potency compared to the parental compound CID755673. This improved analog 
also demonstrated increased inhibition of PMA-induced autophosphorylation of endogenous PKD1 in 
LNCaP prostate cancer cells with an EC50 of 2.2 µM, which represents a ca. 5-fold improvement in 
activity over CID755673, which has an EC50 of 11.8 µM. 
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Table 8. Chemical structures and PKD1 inhibitory activities of zone IV modifications. 
S
N
S
R2
W
R5
 
Entry Compound 
Structure  IC50 
W R2 R5  % PKD1 activity at 1 µM Radiometric PKD1 (µM)a 
1 kb-NB165-16 O OMe Me   4.57 ± 0.78 (n = 2) 
2 kb-NB165-17 O OH Me   0.45 ± 0.05 (n = 2) 
3 kb-NB165-75 O OH (CH2)2NH2  55.6 (n = 1) 0.757 (n = 1) 
4 kb-NB165-81 -- OBn H  78.3 (n = 1) 39.6 (n = 1) 
5 kb-NB165-83 -- OH H  92.4 (n = 1) 16.4 (n = 1) 
a
 PKD1 IC50 was determined using a radiometric kinase activity assay as previously described [52]. 
Each IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration 
in each experiment; n = number of independent experiments.  
 
However, despite the improvement of in vitro and cellular activities, in vivo studies revealed a short 
plasma half-life for this compound. In order to enhance the resistance of kb-NB142-70 towards phase I 
and II metabolism, modifications to zone I were explored with the goal to install a more electron-
deficient heteroarene ring (Table 9). 
Table 9. Chemical structures and PKD1 inhibitory activities of analogs with zone I 
modifications to the pyrimidine scaffold. 
N
N
S
NH
S
R2
O
R4
C4
 
Entry Compound 
Structure  IC50  
 R2 R4  Radiometric PKD1 (µM)a Cellular PKD1 (µM)b 
1 kmg-NB4-23  OMe H  0.12 ± 0.03 (n = 4) 6.8 ± 1.3 (n = 3) 
2 kmg-NB4-69A  OH H  25.3 (n = 1) n.d. 
3 kmg-NB5-13C  OMe OMe  >30.0 (n = 2) n.d. 
4 kmg-NB5-15A  OMe OH  >30.0 (n = 2) n.d. 
a
 PKD1 IC50 was determined using a radiometric kinase activity assay as previously described [52]. 
Each IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration 
in each experiment; n = number of independent experiments. b Cellular IC50 was determined by 
densitometry analysis of Western blotting data for PKD1 autophosphorylation at S916 in LNCaP 
cells as previously described [53]. Each IC50 was calculated as the mean ± SEM of at least three 
independent experiments; n = number of independent experiments. 
 
Gratifyingly, the methoxypyrimidine kmg-NB4-23 exhibited an IC50 of 124 nM, which represents 
only a slight decrease in activity compared to that of the parent compound, kb-NB165-09. This result 
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not only validates our design, but also suggests that the zone I binding pocket is tolerant to a decrease 
in electron density in the aryl region. Surprisingly, the hydroxy analog kmg-NB4-69A showed a 
significant loss in activity relative to the parental compound, kb-NB142-70. This effect can be 
attributed to the susceptibility of the C-4 position of the pyrimidine towards nucleophilic attack [56]; 
the heterocycle spontaneously degrades in protic solvents, resulting in reduced inhibitory activity 
towards PKD1. More hydrolytically stable pyrimidine analogs containing a substituent at the R4 
position also exhibited a dramatic loss in activity, which is consistent with the general SAR results and 
provides additional support for a sterically limited zone I binding pocket. Unfortunately, the low 
aqueous solubility (<0.4 mg/mL even in the presence of lipophilic solubilizing agents) of kmg-NB4-23 
prevented the in vivo evaluation of this compound. 
2.3. Synthetic chemistry 
CID755673 was initially formed in conjunction with CID797718 in a synthetic route starting with 
commercially available ε-caprolactam, which was dibrominated at the α-position [57], and then treated 
with piperidine to afford the known α-oxolactam enamine 4 (Scheme 1) [58].  
Scheme 1. Synthesis of CID755673 and CID797718.a  
NH
O
NH
O
Br
Br NH
O
N
O
O
O
NH
H
N O
O
NH
O
HO
HO
O
NH
O
HO
a, 76%
b, 91%
NH
c, 77%
d
CID755673 CID797718
83% 8%
3 4 5
 
a Reagents and conditions: (a) Br2, PCl5, ZnI2, CHCl3, 0 °C to rt. (b) reflux. (c) EtOH, rt. (d) conc. 
HCl, reflux. 
 
A Nenitzescu reaction between 4 and para-benzoquinone resulted in the formation of cyclic adduct 
5, which was in turn subjected to heating in aqueous acid [59] to provide the desired CID755673. 
Although CID797718 was a byproduct of the synthesis of the target compound CID755673, it showed 
moderate activity and was therefore a desirable starting point for analog synthesis (Scheme 2). 
Functionalizations of this compound involved O- and N-alkylations, as well as chlorination across the 
aryl moiety. Allylation and TBS-protection of the phenolic hydroxy group of the parental compound, 
CID797718, provided the derivatives kb-NB77-83 and kb-NB77-78 in good yields. Treatment of kb-
NB77-78 with CbzCl under basic conditions afforded the desilylated carbamate kb-NB77-91.  
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Scheme 2. Functionalization of the chromenopyridine-based inhibitor CID797718.a 
O
NH
O
HO
CID797718
O
NR5
O
R2
kb-NB77-83, R2 = OAllyl, R5 = H, 68%
kb-NB77-78, R2 = OTBS, R5 = H, 94%
kb-NB77-91, R2 = OH, R5 = Cbz
a or b
c
65%
 
a Reagents and conditions: (a) AllylBr, K2CO3. (b) TBSCl, i-Pr2NEt. (c) CbzCl, Na2CO3. 
 
Introduction of a chlorine atom to the chromenopyridine scaffold was achieved by treating enamine 
4 with 2-chloro-1,4-benzoquinone, followed by the same acid-promoted cis-trans isomerization-
elimination as aforementioned in Scheme 1 (Scheme 3). The chlorinated analogs were isolated as a 
separable mixture of isomers. Unfortunately, all of the chromenopyridine-based analogs were inactive 
in the PKD1 inhibition assays, and therefore this scaffold was abandoned.  
Scheme 3. Synthesis of the chlorinated analogs of CID797718 and CID755673.a 
O
NH
H
N O
HO
O
NH
O
HO
b
ClO
NH
O
HO
Cl
O
NH
O
HO
Cl
kb-NB96-47-1
6%
kb-NB96-47-2
42%
kb-NB96-47-5
5%
Cl
NH
O
N
a, 54%
O
O
Cl
70:30 Mixture
O
NH
H
N O
HO
Cl
4
6a 6b
 
a Reagents and conditions: (a) acetone, rt. (b) AcOH, 40 °C; then reflux. 
 
Our studies on the modification of CID755673 began with the azepinone ring (Scheme 4). The 
syntheses of 6- and 8-membered ring analogs were carried out in an analogous manner to the sequence 
shown in Scheme 1. The acid-mediated piperidine elimination reaction of the 8-membered ring 
derivative 7b proceeded with complete chemoselectivity toward the formation of the desired product 
kb-NB96-53. In contrast, treatment of 7a with acetic acid provided the N-acetylated analog of the 
desired compound and the corresponding chromenopyrrole as the major products. Attempts to cleave 
the N-acetyl functionality to obtain the desired analog kb-NB123-23A were unsuccessful. Gratifyingly, 
subjecting 7a to mCPBA at elevated temperatures afforded the desired 6-membered azepinone ring 
analog, kb-123-23A, in good yield. With the 6- and 8-membered ring analogs in hand, we next 
substituted the phenolic hydroxyl group and alkylated the azepinone amide nitrogen atom (Scheme 4).  
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Scheme 4. Functionalization of the 6- and 8-membered azepinone analogs.a 
kb-NB123-23A, n = 0, 77%
kb-NB96-53, n = 2, 65%
O
NH
H
N O
HO
n
7a, n = 0 
7b, n = 2
O
NH
O
HO
n
a or b c or d
O
N
O
R2
n
R5
kb-NB123-32, n = 0, R2 = OMe, R5 = H, 94%
kb-NB123-37, n = 0, R2 = OMe, R5 = Me, 83%
kb-NB96-59, n = 2, R2 = OMe, R5 = Me, 58%
 
a Reagents and conditions: (a) n = 0, DCE, 0.1 M aq. NaHCO3, m-CPBA, reflux. (b) n = 2, AcOH, 
40 °C; then reflux. (c) MeI, K2CO3. (d) MeI, KOt-Bu. 
 
Treatment of kb-NB123-23A with MeI and K2CO3 provided the O-methylated compound, kb-
NB123-32, while use of a stronger base such as KOt-Bu gave the desired dimethylated analog, kb-
NB123-37, in good yield. The 8-membered dimethylated product kb-NB96-59 was obtained in a 
similar manner to kb-NB123-37, although only in modest yield. 
Due to the lack of potency improvements for the 6- and 8-membered azepinone analogs, further 
modifications to the aryl region of the parental compound CID755673 were explored. 
Functionalization of the phenol was achieved by treatment of CID755675 with base in the presence of 
an electrophile (Table 10, entries 1–4).  
Table 10. Functionalizations of CID755673.  
O
NH
O
HO
CID755673
conditions
O
N
O
R2
R1
R3
R5
 
Entry Conditions Structure Yield, % Product 
R1 R2 R3 R5 
1 MeI, K2CO3 H OMe H H 74 kb-NB77-56 
2 AllylBr, K2CO3 H OAllyl H H 69 kb-NB77-84 
3 TBSCl, i-Pr2NEt H OTBS H H 91 kb-NB77-77 
4 AcCl (2 equiv), DMAP H OAc H H 91 kb-NB123-36 
5 MeI, KOt-Bu H OMe H Me 34 kb-NB96-04 
6 AcCl (3 equiv), DMAP H OAc H Ac 33 kb-NB123-45-1 
7 N-Chlorosuccinimide (1.05 equiv) Cl OH H H 86 kb-NB77-88 
8 Selectfluor® F OH H H 29 kb-NB96-21 
9 N-Chlorosuccinimide (2 equiv) Cl OH Cl H 73 kb-NB96-43 
 
The dimethylated compound kb-NB96-04 and the diacylated compound kb-NB123-45-1 were 
obtained in a similar manner by the use of either a stronger base (KOt-Bu) or additional equivalents of 
the desired electrophile, respectively (Table 10, entries 5 and 6). Modification of the aryl region also 
included additions of halogens (Table 10, entries 7–9). These derivatives could be obtained by the 
treatment of CID755673 with either N-chlorosuccinimide in the case of the chlorinated analogs kb-
NB77-88 and kb-NB96-43, or Selectfluor® in the case of the fluorinated analog kb-NB96-21.  
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Further modifications of these analogs were carried out in order to obtain a more complete SAR for 
the benzofuroazepinone series (Scheme 5). O-Allylation and N-methylation were performed on kb-
NB77-88 and kb-NB77-77, respectively. Additionally, the microwave-mediated Claisen rearrangement 
of the O-allylated-benzoxoloazepinolone kb-NB77-84 provided the target compound kb-NB96-02 
with the allyl functionality at the R1 position. Protection of the phenol of kb-NB96-02 with a silyl 
group provided a derivative which could be subjected to Ru-catalyzed olefin isomerization conditions. 
Subsequent TBS deprotection provided the isomerized product kb-NB96-30 in modest yield over the 
three steps.  
Scheme 5. Functionalizations of the benzofuran-based analogs.a 
O
NH
O
R2
R1
O
N
O
R2
R1
kb-NB96-50, R1 = Cl, R2 = OAllyl, R5 = H, 83%
kb-NB142-25, R1 = H, R2 = OH, R5 = Me, 16%
kb-NB96-02, R1 = Allyl, R2 = OH, R5 = H, 87%
kb-NB77-88, R1 = Cl, R2 = OH
kb-NB77-77, R1 = H, R2 = OTBS 
kb-NB77-84, R1 = H, R2 = OAllyl
a, b, or c
d
R5
kb-NB96-30, R1 = 2-Me-vinyl, R2 = OH, R5 = H, 20%
 
a Reagents and conditions: (a) Allyl-Br, K2CO3, rt. (b) i.) NaH, MeI, DMF, 50 °C; ii.) TBAF, THF, 
rt. (c) MWI, 220 °C. (d) i.) TBSCl, i-Pr2Et, DMF, rt; ii.) RuClH(CO)(PPh3), EtOH, reflux; iii.) 
TBAF, THF, rt. 
 
In addition to alkylations and acetylations of the amide moiety, we also synthesized kb-NB165-15 
to evaluate the effect of the isoelectronic replacement of the amide with an imidazoline ring  
(Scheme 6).  
Scheme 6. Isosteric replacement of the amide moiety of CID755673 with an imidazoline.a 
O
NH
O
R2
CID755673, R2 = OH 
kb-NB142-32, R2 = OTIPS
a
93%
O
N
O
TIPSO
OBn
BnO I
b, 89%
c
58%
O
N
O
HO
N3
d
55% O
N
S
TIPSO
NHBoc
O
NHO
N
e
20%
9
10 kb-NB165-15
8
 
a
 Reagents and conditions: (a) TIPSCl, Et3N, DMAP, DMF, 50 °C. (b) n-BuLi, THF, –30 °C to 
reflux. (c) i) NH4HCO2, Pd/C, MeOH, reflux; ii) MsCl, Et3N, DCM, 0 °C to rt; iii) NaN3, DMF,  
90 °C. (d) i) TIPSCl, Et3N, DMAP, DMF, 50 °C; ii) H2, Pd(OH)2, Boc2O, EtOAc, rt; iii) 
Lawesson’s reagent, toluene, 100 °C. (e) i) MeI, rt; ii) TFA, DCM, 0 °C; then aq. NaOH; iii) CsF, 
MeCN, reflux.  
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A TIPS protection of the parental compound CID755673 followed by N-alkylation provided 8. 
Debenzylation by transfer hydrogenation, mesylation of the primary alcohol, and displacement of the 
resulting mesylate with sodium azide afforded the desired alkyl azide 9 in good yield over the three 
steps. After protection of the phenol, the alkyl azide was reduced to the amine and protected, prior to 
treatment with Lawesson’s reagent to furnish thiolactam 10. Cyclodethionation of thiolactam 10 [60] 
and subsequent TIPS deprotection delivered the desired imidazole containing analog, kb-NB165-15.      
At this time, all modifications to the azepinone ring including altering the ring size, N-
alkylations/acetylations, and isoelectronic replacements of the amide moiety had resulted in inhibitors 
with either reduced potency toward PKD1 or no inhibitory effect at all. Thus, we explored the 
introduction of functionality on the azepinone methylene groups to determine if this region of the 
molecule could be optimized further (Scheme 7).  
Scheme 7. Fuctionalization of the azepinone moiety of CID755673.a 
O
NH
O
AcO
kb-NB123-36
O
NH
O
R2
O
O
NH
O
HO
RN
O
NH
O
HO
HO
11, R2 = OAc
kb-NB123-63, R2 = OH
kb-NB142-05, R = NHPh, 13%
kb-NB142-11, R = NHTs, 46%
kb-NB142-10, R = OBn, 74%
kb-NB123-89
a
89%
c
d
79%
b
38%
 
a
 Reagents and conditions: (a) PDC, TBHP, air, pyr/PhCl/MeCN, Al2O3, rt, sonication. (b) K2CO3, 
MeOH, rt. (c) RNH2(·HCl), MeOH or EtOH, rt to reflux. (d) NaBH4, THF/EtOH, rt. 
 
The synthesis of these analogs began with the oxidation of the O-acetylated derivative kb-NB123-
36 with PDC-TBHP [61] in the presence of neutral alumina in order to install the desired ketone (11). 
The use of sonication proved to significantly improve both the yields and reproducibility of this 
oxidation. Subsequent acetyl deprotection in methanolic potassium carbonate solution provided kb-
NB123-63. Access to further functionalized derivatives was achieved by acid-catalyzed condensation 
of kb-NB123-63 with O-benzylhydroxylamine or N-substituted hydrazines (Scheme 7). The newly 
installed keto functionality was reduced using sodium borohydride to furnish the hydroxy derivative 
kb-NB123-89. 
We also investigated the replacement of the benzofuran core by a β-carboline scaffold (Scheme 8). 
β-Carbolines kb-NB123-57 and kb-NB123-59 were prepared from phenylhydrazine hydrochloride 14 
[62,63] via a Fischer-like indole synthesis with the corresponding 6- and 7-membered ring α-keto 
lactams 12 and 13. Lactams 12 and 13 were obtained in situ upon acid-catalyzed hydrolysis of the 
corresponding enamines [64]. Debenzylation of the resulting β-carbolines by transfer hydrogenation 
furnished the final phenol derivatives [63]. The aniline analogs, kb-NB123-93 [65] and kb-NB123-94, 
were synthesized in a similar manner, starting from hydrazine hydrochloride 15 [66]. Subsequent 
cleavage of the acetyl group afforded the free amino β-carbolines (Scheme 8) [65]. 
Pharmaceutics 2011, 3                   
 
 
202
Scheme 8. Replacement of the benzofuran scaffold by a β-carboline.a  
N
H
NH
O
R2
NH
O
R2
N
H
N
NH2
a
12, n = 0
13, n = 1
14, R2 = OBn
15, R2 = NHAc
⋅HCl nn
R2 = OBn                      R2 = NHAc
n = 0      kb-NB123-52, 52%      kb-NB123-93, 24%
n = 1      kb-NB123-53, 53%      kb-NB123-94, 68%
R2 = OH                        R2 = NH2
n = 0      kb-NB123-59, 95%      kb-NB142-08, 69%
n = 1      kb-NB123-57, 89%      kb-NB142-01, 68%
b c
 
a
 Reagents and conditions: (a) H2SO4 or H3PO4, EtOH, reflux. (b) NH4HCO2, Pd/C, MeOH, reflux. 
(c) aq. HCl, reflux; then NaOH or Na2CO3. 
 
We also synthesized a thio variant of the benzofuroazepinone scaffold to study the effects of sulfur 
incorporation (Scheme 9).  
 
Scheme 9. Synthesis of benzothienothiazepinone-based lead compound kb-NB142-70 and 
zone I modifications.a 
R2 CO2H
R2 = OH
a, 92%
S
BnO
CO2Me
Cl
b
HS NH2
c
S
NH
S
O
R2
kb-NB123-66, R2 = OBn, 87%
16, R2 = OBn
kb-NB142-70, R2 = OH, 93%
kb-NB165-09, R2 = OMe, 92%
17
47%
S
CO2Me
Cl
18
5%
OBn
+
⋅HCl
S
NH
S
O
kb-NB184-38, R4 = OBn, 53%
d
e
kb-NB184-40, R4 = OH, 73%
kb-NB184-44, R4 = OMe, 99%
R4
 
a
 Reagents and conditions: (a) BnBr, NaOH, EtOH, rt. (b) i) SOCl2, pyr, DMF, PhCl,  
120 °C; ii) Et3N, MeOH, reflux. (c) DBU, DMF, rt to 70 °C. (d) BBr3, DCM, –20 °C to rt. (e) MeI, 
K2CO3, DMF, rt.  
 
This analog was constructed by a thionyl chloride-mediated Higa cyclization [67] of benzyl 
protected hydroxycinnamate 16 to a benzo[b]thiophene derived acid chloride, which was subsequently 
converted to the methyl ester 17. Treatment of 17 with cysteamine hydrochloride in the presence of 
DBU furnished the benzyloxy-benzothienothiazepinone kb-NB123-66 [68]. Deprotection of the aryl 
benzyl ether kb-NB123-66 with boron tribromide provided kb-NB142-70 in good yields, and 
subsequent O-methylation gave kb-NB165-09 in excellent yield (Scheme 9). Gratifyingly, kb-NB142-
70 was identified as the most potent analog with an IC50 of 28.3 nM for PKD1, which represents nearly 
Pharmaceutics 2011, 3                   
 
 
203
7-fold higher potency over the parental benzofuroazepinone CID755673. We therefore dissected this 
lead compound into four major structural zones in order to further probe the SAR, as shown in  
Figure 2.  
In zone I, we modified the substituent on the phenolic hydroxyl group and the position of this group 
(Scheme 9). The positional isomer 18 could be isolated as a byproduct from the thionyl chloride-
mediated cyclization of 16. Subsequent construction of the thiazepinone ring could be achieved via 
one-pot nucleophilic displacement-condensation reaction of 18 with cysteamine hydrochloride in a 
similar manner to the lead compound kb-NB142-70. Modification of this isomer by standard alkylation 
and protection-deprotection strategies provided the desired zone I analogs (Scheme 9). Zone I 
modifications also involved halogenations of the aryl moiety. Standard iodination conditions led to 
analog kb-NB165-31 ([Scheme 10 (a)].  
Scheme 10. Zone I structural modifications.a 
(a) 
S
NH
S
O
HO
kb-NB142-70
S
NH
S
O
HO
kb-NB165-31
a
66%
I
 
(b)  
S
NH
S
O
MeO
kb-NB165-09
S
NH
S
O
MeO
kb-NB184-45
b
54%
O
S
NH
S
O
HO
kb-NB184-52
c
25%
Br
 
a
 Reagents and conditions: (a) ICl, n-BuNH2, THF, –40 to 0 °C. (b) H2O2, TFA, DCM,  
0 °C to rt. (c) BBr3, DCM, –20 °C to rt.  
 
In contrast, the brominated analog kb-184-52 was synthesized from the corresponding sulfoxide kb-
NB184-45 upon treatment with BBr3 [Scheme 10 (b)]. Additional zone I modifications, which included 
replacement of the phenol group by nitrogen, required the development of an alternative route (Scheme 
11 and Table 11). Nucleophilic aromatic substitution of methyl 2-chloro-5-nitrobenzoate by methyl 
thioglycolate anion followed by immediate Dieckman cyclization [63,69] afforded the benzothiophene 
precursor 19. Cyclization of the corresponding triflate 20 with cysteamine hydrochloride provided the 
desired tricyclic core 21 in 50% yield (67% based on recovered starting material 19, Scheme 11). 
Subsequent reduction of the nitro group furnished aniline mcf292-03, which was further functionalized 
by treatment with t-butyl nitrite and TMS-azide using Moses’ method [70] to yield the aryl azide, 
mcf292-08 (Table 11, entry 1). The synthesis of the isothiocyanate mcf292-05 was realized by 
subjecting mcf292-03 to the modified Schotten-Baumann conditions reported by Nowick and co-
workers [71] (Table 11, entry 2). Lastly, treatment of mcf292-03 with chlororacetyl chloride in the 
presence of 2,6-lutidine provided the desired chloroacetyl analog mcf292-09 in modest yield over two 
steps (Table 11, entry 3). 
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Scheme 11. Synthesis of the aminobenzothienothiazepinone analog mcf292-03.a  
O2N CO2Me
Cl
CO2MeHS O2N
S
CO2Me
OR
a, 88% S
R2 NH
S
Oc, 50% (67% b.r.s.m. 19)
HS NH2
19, R = H
b, 93% 21, R2 = NO2
d
mcf292-03, R2 = NH2
20, R = Tf
⋅HCl
 
a
 Reagents and conditions: (a) Et3N, MeOH, 40–50 °C. (b) Tf2O, Et3N, DMAP, DCM, rt. (c) DBU, 
DMF, rt to 70 °C. (d) SnCl2, EtOH, reflux. 
Table 11. Zone I modifications based on mcf292-03. 
S
H2N NH
S
O
conditions
S
R2 NH
S
O
mcf292-03
 
Entry Conditions Structure Yield, %  (from 21) Product R2 
1 tBuONO, TMSN3, MeCN, rt N3 38% mcf292-08 
2 CSCl2, NaHCO3, CHCl3/H2O, rt NCS 41% mcf292-05 
3 ClCH2COCl, 2,6-lutidine, DCM, rt NHCOCH2Cl 46% mcf292-09 
 
In our pursuit of zone II SAR, the sulfur ring atom of 17 was oxidized with trifluoroperacetic acid to 
the 3-chlorobenzo[b]thiophene-1-oxide 22 (Scheme 12). The vinylogous chloride 22 was then 
converted to the corresponding benzyloxybenzothienothiazepinone-6-oxide 23, which upon benzyl 
deprotection and methylation provided the desired sulfoxide analogs, kb-NB184-22 and kb-NB184-
25, respectively (Scheme 12). 
Scheme 12. Zone II structural modifications.a 
b, 22% S
NH
S
O
R2
23, R2 = OBn
c, 80%
d, 58%
kb-NB184-22, R2 = OH
kb-NB184-25, R2 = OMe
O
HS NH2
⋅HCl
Y
BnO
CO2Me
Cl
17, Y = S
22, Y = S=O
a, 73%
 
a
 Reagents and conditions: (a) H2O2, TFA, DCM, 0 °C to rt. (b) DBU, DMF, rt to 70 °C. (c) BBr3, 
DCM, –20 °C to rt. (d) MeI, K2CO3, DMF, rt.  
Zone III modifications included oxidations of the thiazepinone ring sulfur atom and variation of the 
thiazepinone ring size [Schemes 10 (b) and 13]. Selective oxidation of the thiazepinone ring sulfur 
atom could be achieved by treatment of kb-NB165-09 with peracid to furnish kb-NB184-45, as shown 
in Scheme 10 (b). Preparation of the 8-membered thiazepinone ring analog began with the synthesis of 
25 via the ring opening of thiazinane-thione 24 [72] (Scheme 13). Aminothiol 25 was isolated as a 
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thiol/disulfide mixture and used directly in the aforementioned cyclocondensation-deprotection 
sequence to provide the desired 8-membered thiazepinone analogs (Scheme 13). 
Scheme 13. Zone III structural modifications.a 
HO NH2 N
H
S
S
HS NH2
25
+
a
67%
b
64% 
mass recov.
c
42%
S
R2
NH
S
O
kb-NB165-89, R2 = OBn
d, 92%
e, 77%
kb-NB165-92, R2 = OH
kb-NB184-02, R2 = OMe
⋅HCl
24
1:1.3 disulfide/thiol
(S NH2)2
⋅HCl
 
a
 Reagents and conditions: (a) i) ClSO3H, CCl4, rt; ii) CS2, NaOH, EtOH/H2O, 0 °C to reflux. (b) 
conc. HCl, reflux, N2. (c) 17, DBU, DMF, rt to 70 °C. (d) BBr3, DCM, –20 °C to rt. (e) MeI, 
K2CO3, DMF, rt. 
 
In an effort to further assess the SAR effects of modifying zone III, we investigated the synthesis of 
benzothiophene analogs linked to a three-carbon chain by an ether or amine function, instead of the 
thioether present in the lead compound. Key to accomplishing the synthesis of the ether analog kb-
NB184-36 was the use of the activated chloride 22, which was obtained via oxidation of the 
benzothiophene sulfur to the corresponding sulfoxide according to Scheme 12. A DMAP-catalyzed 
nucleophilic displacement of the chlorine atom with alcohol 26 afforded the cyclization precursor 27, 
which upon N-Boc deprotection and subsequent tandem cyclization-deoxygenation led to the 
benzyloxybenzothienooxazocinone analog kb-NB184-36 [Scheme 14 (a)]. The methoxy analog kb-
NB184-57 was synthesized in a similar manner [Scheme 14 (b)]. 
Scheme 14. Zone III structural modifications.a 
     (a) 
S
BnO
CO2Me
Cl
22
O
HO NHBoc
26
a, 18% S
BnO
CO2Me
O
27
O
S
BnO
NH
O
O
b
51%
NHBoc
kb-NB184-36
 
     (b) 
MeO CO2H
Y
MeO
CO2Me
Cl
c
28%
28, Y = S
29, Y = S=O
d, 80%
e
12% S
MeO
NH
O
O
kb-NB184-57
 
a
 Reagents and conditions: (a) i) DMAP, DCE, rt; ii) 26, i-Pr2NEt, DCE, 60 °C. (b) i) 4 N 
HCl/dioxane, rt; ii) NaOMe, MeOH, reflux. (c) i) SOCl2, pyr, DMF, PhCl, 120 °C; ii) Et3N, 
MeOH, reflux. (d) H2O2, TFA, DCM, 0 °C to rt. (e) i) 26, DMAP, i-Pr2NEt, DCM, reflux; ii) 4 N 
HCl/dioxane, rt; iii) NaOMe, MeOH, reflux. 
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In an analogous manner, the synthesis of diazepinone analog 31 was attempted; however, precursor 
30 failed to undergo cyclization under both base- and Cu-mediated conditions [Scheme 15 (a)] [73]. 
Therefore, we opted for a nucleophilic displacement at the activated chlorine atom in 29 with 
aminopropanol, followed by a TMSI-mediated deoxygenation of 32 to provide kb-NB184-80 [Scheme 
15 (b)]. Investigations regarding the use of these intermediates [Scheme 15 (b)] as precursors for the 
desired analog 31 are still under investigation.    
Scheme 15. Zone III structural modifications.a 
     (a) 
S
BnO
CO2Me
Cl
17
S
BnO
Cl
30
a, 70% S
NH
HN
O
BnONH
O
BocHN
b or cH2N
NHBoc
31
 
      (b) 
S
MeO
CO2Me
Cl
29
O
Y
MeO
CO2Me
HN
32, Y = S=O
kb-NB184-80, Y = S
e, 71%
OH
H2N OH
d, 80%
 
a
 Reagents and conditions: (a) TBD, 75 °C. (b) NaH. (c) i) acid; ii) Cu2O, collidine. (d) NaH, 
THF/DMF, 0 °C to rt. (e) TMSCl, NaI, MeCN/THF, rt.  
 
Finally, we explored structural modifications of zone IV by alkylation of the amide nitrogen and 
reduction of the amide (Schemes 16 and 17, respectively).  
Scheme 16. Zone IV structural modifications.a 
kb-NB165-16, R2 = OMe, R5 = Me, 71%
kb-NB165-17, R2 = OH, R5 = Me, 38%
S
N
S
O
R2
S
N
S
O
R2
d, 80%
c, quant. R
33, R2 = OTIPS, R = OBn
e, 75%
f, 64%
34, R2 = OH, R = N3
35, R2 = OBoc, R = NHBoc
g, quant.
kb-NB165-75, R2 = OH, R = NH2
BnO I
R5
kb-NB123-66, R2 = OBn, R5 = H
kb-NB142-70, R2 = OH, R5 = H
a, 71%
b, 38%
 
a
 Reagents and conditions: (a) NaH, MeI, DMF, 50 °C. (b) i) NaH, MeI, DMF, rt; ii) BBr3, DCM, –
20 °C to rt. (c) TIPSCl, Et3N, DMAP, DMF, 50 °C. (d) n-BuLi, THF, –20 °C to reflux. (e) i) BBr3, 
DCM, –20 °C to rt; ii) MsCl, Et3N, DCM; iii) NaN3, DMF, 90 °C. (f) i) PPh3, THF, rt; then H2O; 
ii) Boc2O, Et3N, DCM, rt. (g) 4 N HCl/dioxane, MeOH, rt.  
 
The N-methylated analog kb-NB165-17 was prepared from the benzyloxybenzothiazepinone kb-
NB123-66 (Scheme 9) through an alkylation-deprotection sequence, while the dialkylated kb-NB165-
16 was obtained in one step by treatment with NaH and MeI. The synthesis of kb-NB165-75 was 
accomplished via the N-alkylation of silyl protected kb-NB142-70 with the corresponding alkyl iodide, 
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followed by functional group interconversions and a final deprotection to furnish the desired analog 
kb-NB165-75. The amide reduction of thiolactam 36 proceeded poorly upon treatment with Raney-
Nickel in THF due to a competitive cleavage of the other C-S bonds present in this system (Scheme 
17). Nonetheless, we were able to isolate kb-NB165-81 in low yields and debenzylate it to afford the 
desired phenol kb-NB165-83 (Scheme 17).      
Scheme 17. Zone IV structural modifications (continued).a 
S
NH
S
W
BnO
S
NH
S
R2b
15%
kb-NB123-66, W = O
36, W = S
a,
54%
kb-NB165-81, R2 = OBnc, 
70% kb-NB165-83, R2 = OH
 
a
 Reagents and conditions: (a) Belleau’s reagent, toluene, 100 °C. (b) H2, Ra-Ni, THF, rt. (c) BBr3, 
DCM, –20 °C to rt.  
 
As mentioned in Section 2.2, preliminary in vivo studies revealed that the lead compound kb-
NB142-70 and the methoxy analog kb-NB165-09 possessed a short plasma half-life (data not shown). 
Therefore, we further explored a zone I modification of kb-NB142-70 to install a more electron-
deficient pyrimidine moiety in place of the phenol ether, a known site of active phase I and II 
metabolism. The synthetic route to arrive at this new thiazepinothiophenopyrimidinone scaffold is 
summarized in Scheme 18.  
Scheme 18. Synthesis of thiazepinothiophenopyrimidinone analogs.a 
S
H2N
MeO2C
N
NR
R
S
a
65% N
NR
S
37, R = OH
b, 79%
39, R = Cl
d, 88%
c
90% N
NMeO
S
Br
N
NMeO
S
Br
CO2Me
N
N
S
MeO NH
S
Og, 68%
HS NH2
⋅HCl
41 42
kmg-NB4-23
e
40%
f
97%
38, R = Cl 40, R = OMe
h
85% N
N
S
HO NH
S
O
kmg-NB4-69A
4
7
2
6
4
7
2
6
4
72
6
4
72
6
⋅HCl
 
a Reagents and conditions: (a) i) KOCN, AcOH, H2O, rt, 20 h; ii) 2 M NaOH, rt. (b) POCl3, MeCN, 
reflux. (c) H2, Pd/C, EtOH, Na2CO3, rt. (d) NaOMe, MeOH, reflux. (e) AcOH, Br2, 70 °C. (f) i) 
TMPMgCl·LiCl, –50 °C; ii) MeCO2CN. (g) DBU, DMF, rt; then 70 °C. (h) 4 M HCl/dioxane,  
80 °C. 
 
Starting with commercially available methyl 3-aminothiophene-2-carboxylate, formation of the 
pyrimidine moiety using potassium cyanate and chlorination with POCl3 provided dichloride 38 [74]. 
Regioselective palladium-catalyzed hydrogenolysis of 38 in the presence of Na2CO3 occurred 
exclusively at the C-4 position [75], and substitution of the remaining C-2 chloride with methoxide 
provided 40 in 79% yield over the two steps. Electrophilic bromination of 40 using bromine in acetic 
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acid gave the desired C-7 bromo compound 41. Functionalization at C-6 was accomplished via 
selective metalation and trapping with Mander’s reagent to provide the required cyclization precursor 
42 [76]. Formation of the thiazepinone moiety was achieved by a one-pot nucleophilic displacement-
condensation of 42 with cysteamine hydrochloride to provide the desired methoxypyrimidine kmg-
NB4-23 in good yield. The structure of kmg-NB4-23 was confirmed by x-ray analysis (Figure 3; this 
structure has been deposited at the Cambridge Crystallographic Data Centre and allocated the 
deposition number CCDC 822403). When kmg-NB4-23 was subjected to 4 M HCl in 1,4-dioxane, the 
desired hydroxypyrimidine kmg-NB4-69A was formed as the hydrochloride salt (Scheme 18). 
Figure 3. X-ray structure of kmg-NB4-23. 
 
Pyrimidine kmg-NB4-23 is a potent nanomolar inhibitor of PKD, thus confirming the validity of 
our design. In contrast, kmg-NB4-69A had only weak inhibitory effect against PKD. This lack of 
activity is attributed to the instability of the compound towards nucleophilic addition of H2O at the C-4 
position [56]. Efforts to stabilize the C-4 position led to the design of compounds kmg-NB5-13 and 
kmg-NB5-15 (Scheme 19).  
Scheme 19. Synthesis of the thiazepinothiophenopyrimidinone analogs.a 
N
N
S
MeO NH
S
Od, 77%
HS NH2
⋅HCl
kmg-NB5-13
e
77% N
N
S
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OMe OH
N
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S N
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b
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c
82%
7
6
7
6
7
6
OMe OMe
a
92% N
NMeO
S
7
6
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4338
 
a Reagents and conditions: (a) NaOMe, MeOH, reflux, 48 h. (b) AcOH, Br2, rt, 32 h. (c) i) 
TMPMgCl·LiCl, –50 °C, 2 h; ii) MeCO2CN. (d) DBU, DMF, rt, 3 h. (e) KOSiMe3, THF,  
80 °C, 22 h. 
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These analogs were successfully synthesized in a similar manner to kmg-NB4-23 and kmg-NB4-
69A (Scheme 18). Unfortunately, preliminary biological data indicate an absence of inhibitory activity 
for both kmg-NB5-13 and kmg-NB5-15.   
3. Experimental Section  
3.1. General 
Melting points were determined on a Meltemp capillary melting point apparatus fitted with a Fluke 
51 II digital thermometer. Infrared spectra were recorded on a Smiths IdentifyIR ATR spectrometer or 
a Perkin Elmer Spectrum 100 FT-IR spectrometer using the Universal ATR Sampling Accessory for 
both oil and solid compounds. 1H NMR and 13C NMR spectra were obtained on a Bruker Avance 300, 
400 or 600 instrument at 300/75 MHz, 400/100 MHz or 600/150 MHz, respectively. Chemical shifts 
were reported in parts per million (ppm) as referenced to residual solvent. 1H NMR spectra are 
tabulated as follows: chemical shift, multiplicity (app = apparent, b = broad, s = singlet, d = doublet,  
t = triplet, q = quartet, quint = quintuplet, sext, = sextuplet, m = multiplet), number of protons, 
coupling constant(s). 13C NMR were obtained using a proton-decoupled pulse sequence and are 
tabulated by observed peak. Mass spectra were obtained on a Waters Autospec double focusing mass 
spectrometer (EI) or a Waters Q-Tof mass spectrometer (ESI), at the University of Pittsburgh Mass 
Spectrometry facility. 
 
3.2. Characterization data for all final synthetic compounds. 
9-Hydroxy-1,2,3,4-tetrahydro-chromeno[3,4-b]pyridin-5-one (CID797718). Yield: 8%; m.p. (i-PrOH) 
217–218 °C (lit. 213–216 °C) [59]; IR (ATR, neat) 3401, 3305 (br), 2937, 2879, 1662, 1583, 1449, 
1342, 1219, 1184 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.41 (s, 1 H), 7.09 (d, 1 H, J = 9.0 Hz), 6.74 
(d, 1 H, J = 3.0 Hz), 6.66 (dd, 1 H, J = 9.0, 3.0 Hz), 5.91 (s, 1 H), 3.24–3.22 (m, 2 H), 2.59 (t, 2 H,  
J = 6.6 Hz), 1.90–1.85 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 158.1, 154.5, 140.9, 129.8, 122.9, 
116.8, 114.8, 113.4, 106.4, 40.3, 21.6, 20.6; HRMS (ESI) m/z calcd for C12H11NO3 ([M+H]+) 
218.0817, found 218.0802.  
9-Allyloxy-1,2,3,4-tetrahydrochromeno[3,4-b]pyridin-5-one (kb-NB77-83). Yield: 68%; m.p.  
90–91 °C; IR (ATR, neat) 3419, 3394, 2917, 2864, 1702, 1599, 1510, 1189 cm–1; 1H-NMR (CDCl3, 
600 MHz) δ 7.20 (d, 1 H, J = 9.0 Hz), 6.86 (d, 1 H, J = 3.0 Hz), 6.84 (dd, 1 H, J = 9.0, 3.0 Hz),  
6.11–6.04 (m, 1 H), 5.44 (d, 1 H, J = 16.8 Hz), 5.32 (d, 1 H, J = 10.2 Hz), 4.74 (bs, 1 H), 4.57 (d, 2 H,  
J = 5.4 Hz), 3.41–3.37 (m, 2 H), 2.69 (t, 2 H, J = 6.6 Hz), 2.08–2.03 (m, 2 H); 13C-NMR (CDCl3, 150 
MHz) δ 158.8, 155.4, 142.5, 133.3, 129.7, 122.6, 118.0, 117.1, 115.9, 113.0, 106.0, 69.5, 40.6, 21.6, 
20.8; HRMS (ESI) m/z calcd for C15H15NO3 ([M+H]+) 258.1130, found 258.1138. 
9-(tert-Butyldimethylsilyloxy)-1,2,3,4-tetrahydrochromeno[3,4-b]pyridin-5-one (kb-NB77-78). Yield: 
94%; m.p. 117–119 °C; IR (ATR, neat) 3418, 2929, 2856, 1721, 1699, 1602, 1508, 1430, 1251,  
1172 cm–1; 1H-NMR (CDCl3, 600 MHz) δ 7.14 (d, 1 H, J = 9.0 Hz), 6.78 (d, 1 H, J = 3.0 Hz), 6.73 
(dd, 1 H, J = 9.0, 3.0 Hz), 4.72 (bs, 1 H), 3.41–3.35 (m, 2 H), 2.67 (t, 2 H, J = 6.6 Hz), 2.09–2.02 (m, 2 
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H), 1.00 (s, 9 H), 0.21 (s, 6 H); 13C-NMR (DMSO-d6, 150 MHz) δ 157.5, 151.7, 141.9, 129.5, 122.6, 
117.1, 116.63, 116.57, 113.9, 111.0, 25.6 (3 C), 21.1, 20.0, 18.0, –4.5 (2 C); HRMS (ESI) m/z calcd for 
C18H25NO3Si ([M+H]+) 332.1682, found 332.1678. 
 
Benzyl 9-hydroxy-5-oxo-1,2,3,4-tetrahydrochromeno[3,4-b]pyridine-4-carboxylate (kb-NB77-91). 
Yield: 65%; m.p. 235–237 °C; IR (ATR, neat) 3887, 1724, 1679, 1404, 1308, 1261, 1160 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 9.73 (s, 1 H), 7.38–7.33 (m, 4 H), 7.33–7.28 (m, 1 H), 7.23 (d, 1 H,  
J = 9.0 Hz), 6.98–6.95 (m, 2 H), 5.11 (s, 2 H), 3.30–3.50 (m, 2 H), 2.85 (t, 2 H, J = 6.6 Hz), 1.98–1.88 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 156.2, 154.03, 153.99, 144.8, 138.7, 136.1, 128.4 (2 C), 
128.0, 127.7 (2 C), 125.0, 119.6, 118.4, 117.1, 108.5, 67.4, 44.2, 22.5, 22.1; HRMS (ESI) m/z calcd for 
C20H17NO5 ([M+Na]+) 374.1004, found 374.0991. 
 
10-Chloro-9-hydroxy-1,2,3,4-tetrahydrochromeno[3,4-b]pyridin-5-one (kb-NB96-47-1). Yield: 6%; 
m.p. 211–213 °C; IR (ATR, neat) 3434, 3225 (br), 2971, 2906, 1666, 1589, 1509, 1339, 1235 cm–1; 
1H-NMR (DMSO-d6, 600 MHz) δ 10.02 (s, 1 H), 7.10 (d, 1 H, J = 9.0 Hz), 6.85 (d, 1 H, J = 9.0 Hz), 
6.24 (bs, 1 H), 3.25–3.20 (m, 2 H), 3.15 (t, 2 H, J = 6.6 Hz), 1.80–1.74 (m, 2 H); 13C-NMR (DMSO-d6, 
150 MHz) 156.8, 151.0, 140.9, 130.4, 120.7, 115.5, 113.4, 113.1, 112.4, 26.8, 20.9; HRMS (EI) m/z 
calcd for C12H10ClNO3 (M+) 251.0349, found 251.0349. 
 
7-Hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (CID755673). Yield: 83%; m.p. (i-
PrOH) 245–247 °C (lit. 244–247 °C) [59]; IR (ATR, neat) 3187 (br), 3059, 2921, 1680, 1579, 1472, 
1435, 1339, 1166 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.36 (s, 1 H), 8.09 (t, 1 H, J = 4.8 Hz), 7.41 
(d, 1 H, J = 9.0 Hz), 6.92 (d, 1 H, J = 2.4 Hz), 6.90 (dd, 1 H, J = 9.0, 2.4 Hz), 3.24 (dd, 2 H, J = 9,  
4.8 Hz), 2.89 (t, 2 H, J = 6.6 Hz), 2.02–1.98 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.9, 153.9, 
148.1, 144.3, 129.6, 123.5, 116.9, 112.4, 105.1, 41.2, 26.8, 24.3; HRMS (ESI) m/z calcd for 
C12H11NO3 ([M+H]+) 218.0817, found 218.0832. 
 
6-Hydroxy-3,4-dihydrobenzoxolo[2,3-c]pyridin-1(2H)-one (kb-NB123-23A). Yield: 77%; m.p.  
265–268 °C; IR (ATR, neat) 3404, 3158 (bs), 1661, 1588, 1479, 1451, 1339, 1228, 1208, 1184 cm–1; 
1H-NMR (DMSO-d6, 600 MHz) δ 9.43 (s, 1 H), 7.74 (bs, 1 H), 7.47 (d, 1 H, J = 9.0 Hz), 6.98 (d, 1 H, 
J = 2.4 Hz), 6.91 (dd, 1 H, J = 9.0, 2.4 Hz), 3.50 (td, 2 H, J = 7.2, 2.4 Hz), 2.88 (t, 2 H, J = 7.2 Hz); 
13C-NMR (DMSO-d6, 150 MHz) δ 159.4, 153.8, 149.0, 144.5, 126.6, 124.6, 116.4, 112.6, 105.1, 40.3, 
20.0; HRMS (ESI) m/z calcd for C11H9NO3 ([M+H]+) 203.0582, found 203.0588. 
 
6-Methoxy-3,4-dihydrobenzoxolo[2,3-c]pyridin-1(2H)-one (kb-NB123-32) [77]. Yield: 94%; m.p. 
237–241 °C; IR (ATR, neat) 3197, 3088, 2895, 1672, 1585, 1480, 1432, 1329, 1214, 1192 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 7.78 (s, 1 H), 7.58 (d, 1 H, J = 9.0 Hz), 7.26 (d, 1 H, J = 2.4 Hz), 7.06 
(dd, 1 H, J = 9.0 Hz, 2.4 Hz), 3.81 (s, 3 H), 3.52 (td, 2 H, J = 7.2, 2.4 Hz), 2.94 (t, 2 H, J = 7.2 Hz); 
13C-NMR (DMSO-d6, 150 MHz) δ 159.3, 156.0, 149.7, 144.7, 126.4, 125.0, 116.5, 112.9, 103.1, 55.7, 
40.4, 20.1; HRMS (EI) m/z calcd for C12H11NO3 (M+) 217.0739, found 217.0743. 
Pharmaceutics 2011, 3                   
 
 
211
8-Hydroxy-3,4,5,6-tetrahydrobenzoxolo[2,3-c]azocin-1(2H)-one (kb-NB96-53). Yield: 77%; m.p. 
225–232 °C; IR (ATR, neat) 3348, 3166 (br), 2927, 1639, 1578, 1465, 1433, 1216, 1153 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 9.33 (s, 1 H), 7.98 (t, 1 H, J = 6.7 Hz), 7.36 (d, 1 H, J = 8.8 Hz), 6.87 
(d, 1 H, J = 2.2 Hz), 6.85 (dd, 1 H, J = 8.8, 2.4 Hz), 3.32–3.27 (m, 2 H), 2.79–2.74 (m, 2 H), 1.92–1.86 
(m, 2 H), 1.67–1.62 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 162.9, 153.5, 147.4, 142.6, 129.1, 
122.2, 115.4, 111.7, 104.5, 30.2, 22.9, 20.5; HRMS (ESI) m/z calcd for C13H13NO3 ([M+Na]+) 
254.0793, found 254.0773. 
8-Methoxy-2-methyl-3,4,5,6-tetrahydrobenzoxolo[2,3-c]azocin-1(2H)-one (kb-NB96-59). Yield: 58%; 
m.p. 261–264 °C; IR (ATR, neat) 3168, 3038, 2928, 1651, 1581, 1478, 1435, 1210, 1152 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 8.01 (s, 1 H), 7.47 (d, 1 H, J = 9.0 Hz), 7.12 (s, 1 H), 7.00 (d, 1 H,  
J = 9.0 Hz), 3.33–3.28 (m, 2 H), 3.80 (s, 3 H), 2.86–2.81 (m, 2 H), 1.93–1.86 (m, 2 H), 1.69–1.61 (m, 2 
H); 13C-NMR (DMSO-d6, 150 MHz) δ 162.9, 155.8, 148.2, 142.9, 128.9, 122.7, 115.5, 112.1, 102.6, 
55.7, 30.2, 23.0, 20.5; HRMS (ESI) m/z calcd for C14H15NO3 ([M+Na]+) 268.0950, found 268.0970. 
7-Methoxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB77-56). Yield: 74%; m.p.  
261–263 °C; IR (ATR, neat) 3200, 3063, 2936, 1642, 1580, 1474, 1434, 1207, 1163 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 8.13 (t, 1 H, J = 4.8 Hz), 7.53 (d, 1 H, J = 9.0 Hz), 7.18 (d, 1 H, J = 2.4 Hz), 
7.05 (dd, 1 H, J = 9.0, 2.4 Hz), 3.81 (s, 3 H), 3.27 (dd, 2 H, J = 9.0, 5.4 Hz), 2.96 (t, 2 H, J = 6.6 Hz), 
2.06–2.00 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.4, 155.7, 148.4, 144.1, 129.0, 123.5, 
116.4, 112.3, 102.8, 55.7, 40.8, 26.3, 24.0; HRMS (ESI) m/z calcd for C13H14NO3 ([M+H]+) 232.0974, 
found 232.0966. 
7-Allyloxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB77-84). Yield: 69%; m.p.  
198–200 °C; IR (ATR, neat) 3189, 3072, 2968, 2912, 1650, 1602, 1585, 1459, 1422, 1201, 1170 cm–1; 
1H-NMR (DMSO-d6, 600 MHz) δ 8.13 (t, 1 H, J = 4.8 Hz), 7.53 (d, 1 H, J = 9.0 Hz), 7.20 (d, 1 H,  
J = 2.4 Hz), 7.08 (dd, 1 H, J = 9.0, 2.4 Hz), 6.11–6.04 (m, 1 H), 5.43 (dd, 1 H, J = 18, 1.8 Hz), 5.27 
(dd, 1 H, J = 8.4, 1.8 Hz), 4.61 (d, 2 H, J = 5.22), 3.29–3.24 (m, 2 H), 2.94 (t, 2 H, J = 6.6 Hz),  
2.06–1.98 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.4, 154.6, 148.4, 144.1, 133.8, 129.0, 
123.5, 117.5, 116.8, 112.3, 104.1, 68.9, 40.8, 26.3, 23.9; HRMS (ESI) m/z calcd for C15H15NO3 
([M+Na]+) 280.0950, found 280.0959. 
7-Acetoxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB123-36). Yield: 91%; m.p. 
196–197 °C; IR (ATR, neat) 3193, 3083, 2935, 1750, 1663, 1583, 1207, 1157, 1063 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 8.21 (bs, 1 H), 7.66 (d, 1 H, J = 9.0 Hz), 7.47 (d, 1 H, J = 2.4 Hz), 7.22 (dd, 1 
H, J = 9.0, 2.4 Hz), 3.27 (dd, 2 H, J = 8.4, 4.8 Hz), 2.94 (t, 2 H, J = 6.6 Hz), 2.29 (s, 3 H), 2.06–1.99 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 169.7, 161.2, 151.0, 146.3, 144.6, 129.0, 123.5, 122.6, 
113.9, 112.3, 40.8, 26.3, 23.8, 20.9; HRMS (EI) m/z calcd for C14H13NO4 (M+) 259.0845, found 
259.0850. 
7-(tert-Butyldimethylsilyloxy)-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB77-77). 
Yield: 91%; m.p. 209–212 °C; IR (ATR, neat) 3194, 3085, 2952, 2927, 1655, 1579, 1467, 1252, 1202, 
1170 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 8.13 (bs, 1 H), 7.50 (d, 1 H, J = 9.0 Hz), 7.06 (d, 1 H,  
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J = 1.8 Hz), 6.96 (dd, 1 H, J = 8.4, 2.4 Hz), 3.28–3.23 (m, 2 H), 2.93 (t, 2 H, J = 6.6 Hz), 2.04–1.97 
(m, 2 H), 0.97 (s, 9 H), 0.19 (s, 6 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.3, 151.0 148.8, 144.2, 
129.3, 123.3, 120.4, 112.2, 110.3, 40.8, 26.3, 25.6 (3 C), 23.9, 18.0, –4.6 (2 C); HRMS (ESI) m/z calcd 
for C18H25NO3Si ([M+Na]+) 354.1501, found 354.1472. 
 
6-Methoxy-2-methyl-3,4-dihydrobenzoxolo[2,3-c]pyridin-1(2H)-one (kb-NB123-37). Yield: 83%; m.p. 
168–172 °C; IR (ATR, neat) 2920, 1661, 1602, 1485, 1454, 1329, 1212, 1179 cm–1; 1H-NMR (DMSO-
d6, 600 MHz) δ 7.57 (d, 1 H, J = 9.0 Hz), 7.25 (d, 1 H, J = 2.4 Hz), 7.05 (dd, 1 H, J = 9.0,  
2.4 Hz), 3.81 (s, 3 H), 3.69 (t, 2 H, J = 7.2 Hz), 3.01 (t, 2 H, J = 7.2 Hz), 2.98 (s, 3 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 158.5, 156.0, 149.9, 144.5, 123.8, 116.4, 112.9, 103.0, 55.7, 48.6, 33.5, 19.3; 
HRMS (EI) m/z calcd for C13H13NO3 (M+) 231.0895, found 231.0899. 
7-Hydroxy-2-methyl-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB142-25). Yield: 
36%; m.p. 282–284 °C; IR (ATR, neat) 3186, 1615, 1577, 1452, 1407, 1364, 1325, 1187 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 9.36 (s, 1 H), 7.41 (d, 1 H, J = 9.0 Hz), 6.92 (d, 1 H, J = 2.4 Hz), 6.90 
(dd, 1 H, J = 9.0, 2.4 Hz), 3.52–3.49 (m, 2 H), 3.06 (s, 3 H), 2.86 (t, 2 H, J = 6.6 Hz), 2.03–2.09 (m, 2 
H); 13C-NMR (DMSO-d6, 150 MHz) δ 160.0, 153.5, 147.5, 144.0, 129.0, 122.4, 116.3, 111.9, 104.6, 
49.3, 36.2, 25.5, 23.3; HRMS (EI) m/z calcd for C13H13NO3 (M+) 231.0895, found 231.0899. 
 
7-Methoxy-2-methyl-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-04). Yield: 34%; 
m.p. 150–151 °C; IR (ATR, neat) 3008, 2919, 1629, 1579, 1478, 1440, 1428, 1217, 1177 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 7.53 (d, 1 H, J = 9.0 Hz), 7.16 (d, 1 H, J = 2.4 Hz), 7.05 (dd, 1 H,  
J = 9.0, 2.4 Hz), 3.81 (s, 3 H), 3.54–3.50 (m, 2 H), 3.07 (s, 3 H), 2.93 (t, 2 H, J = 6.6 Hz), 2.11–2.05 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 159.9, 155.7, 148.3, 144.3, 128.9, 122.9, 116.3, 112.3, 
102.7, 55.7, 49.3, 36.2, 25.5, 23.4; HRMS (ESI) m/z calcd for C14H15NO3 ([M+Na]+) 268.0950, found 
268.0935. 
2-Acetyl-1-oxo-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-7-yl acetate (kb-NB123-45-1). Yield: 
33%; m.p. 155–157 °C; IR (ATR, neat) 3069, 2949, 1753, 1699, 1669, 1570, 1402, 1363, 1213,  
1168 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 7.75 (d, 1 H, J = 9.0 Hz), 7.61 (s, 1 H, J = 2.4 Hz), 7.31 
(dd, 1 H, J = 9.0, 2.4 Hz), 3.96–3.92 (m, 2 H), 3.03 (t, 2 H, J = 6.0 Hz), 2.45 (s, 3 H), 2.30 (s, 3 H), 
2.08–2.03 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 171.3, 169.6, 162.3, 151.9, 146.6, 144.5, 
128.4, 127.1, 123.1, 114.5, 112.7, 40.9, 26.2, 25.1, 21.6, 20.9; HRMS (EI) m/z calcd for C16H15NO5 
(M+) 301.0950, found 301.0964. 
9-Hydroxy-3,5,6,7-tetrahydro-2H-benzoxolo[2,3-c]imidazo[1,2-a]azepine (kb-NB165-15). Yield: 
40%; m.p. 230–232 °C (dec., brown), 268–270 °C (dec., melts); IR (ATR, neat) 2918, 2871, 2528, 
1624, 1590, 1550, 1445, 1392, 1285, 1195 cm–1; 1H-NMR (CD3OD, 600 MHz) δ 7.34 (d, 1 H,  
J = 9.6 Hz), 6.92–6.90 (m, 2 H), 3.81 (t, 2 H, J = 10.2 Hz), 3.63 (t, 2 H, J = 10.2 Hz), 3.44–3.41 (t, 2 
H, J = 4.8 Hz), 2.95 (t, 2 H, J = 6.0 Hz), 2.22–2.17 (m, 2 H); 13C-NMR (CD3OD, 150 MHz) δ 159.8, 
155.6, 150.3, 142.4, 130.6, 125.8, 117.9, 112.8, 105.6, 55.0, 52.0, 49.4, 26.5, 25.1; HRMS (EI) m/z 
calcd for C14H14N2O2 (M+) 242.1055, found 242.1052. 
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6-Chloro-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB77-88). Yield: 86%; 
m.p. >300 °C; IR (ATR, neat) 3886, 3036 (br), 2928, 1629, 1566, 1428, 1340, 1174 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 10.0 (s, 1 H), 8.22 (t, 1 H, J = 4.8 Hz), 7.43 (d, 1 H, J = 9.0 Hz), 7.10 (d, 1 H, 
J = 9.0 Hz), 3.26–3.20 (m, 4 H), 2.04–1.98 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.1, 149.5, 
147.9, 144.6, 126.0, 123.4, 116.8, 111.4, 110.8, 40.2, 27.0, 26.3; HRMS (ESI) m/z calcd for 
C12H10ClNO3 ([M+Na]+), 274.0247, found 274.0226. 
6-Fluoro-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-21). Yield: 29%; 
m.p. >300 °C; IR (ATR, neat) 3197 (br), 2925, 2385, 1625, 1577, 1477, 1437, 1345, 1032 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 9.67 (bs, 1 H), 8.19 (t, 1 H, J = 4.2 Hz), 7.26 (d, 1 H, J = 9.0 Hz), 7.08 
(dd, 1 H, J
 
= 8.6 Hz, JHF = 8.6 Hz), 3.25 (dd, 2 H, J = 8.4, 4.8 Hz), 3.09 (t, 2 H, J = 6.6 Hz), 2.05–1.97 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.1, 147.8 (d, JCF = 7.5 Hz), 144.3 (d, JCF = 244 Hz), 
143.9, 139.8 (d, JCF = 10.3 Hz), 121.8 (d, JCF = 3.5 Hz), 118.3 (d, JCF = 4.5 Hz), 118.1, 107.4 (d,  
JCF = 4.2 Hz), 40.5, 26.7, 25.4; 19F NMR (DMSO-d6, 400 MHz) δ –149.09 (d, JFH = 8.4 Hz); HRMS 
(ESI) m/z calcd for C12H10FNO3 ([M+Na]+) 258.0542, found 258.0566. 
7-Allyloxy-6-chloro-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-50). Yield: 83%; 
representative experimental data: m.p. 192–194 °C; IR (ATR, neat) 3200, 3075, 2928, 1674, 1650, 
1573, 1464, 1422, 1259, 1173, 1065 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 8.28 (t, 1 H, J = 4.2 Hz), 
7.58 (d, 1 H, J = 9.0 Hz), 7.33 (d, 1 H, J = 9.0 Hz), 6.10–6.02 (m, 1 H), 5.44 (dd, 1 H, J = 17.4,  
1.8 Hz), 5.28 (dd, 1 H, J = 9, 1.8 Hz), 4.69 (s, 2 H), 3.28–3.21 (m, 4 H), 2.05–1.97 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 160.9, 150.1, 148.9, 145.1, 133.5, 126.2, 123.4, 117.7, 115.2, 114.6, 110.8, 
70.4, 30.7, 26.9, 26.3; HRMS (ESI) m/z calcd for C15H14ClNO3 ([M+Na]+) 314.0560, found 314.0540. 
8-Chloro-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-47-5). Yield: 5%; 
representative experimental data: m.p. 327–332 °C; IR (ATR, neat) 3293, 3196 (br), 2938, 1652, 1578, 
1464, 1437, 1233, 1141 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 10.12 (s, 1 H), 8.14 (bs, 1 H), 7.73 (s, 
1 H), 7.11 (s, 1 H), 3.28–3.22 (m, 2 H), 2.89 (t, J = 6.6 Hz, 2 H), 2.03–1.98 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) 161.2, 149.4, 147.0, 144.3, 128.0, 123.0, 120.9, 112.7, 105.7, 40.7, 26.3, 23.7; 
HRMS (ESI) m/z calcd for C12H10ClNO3 ([M+Na]+) 274.0247, found 274.0224. 
6,8-Dichloro-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-43). Yield: 
73%; m.p. 298–301 °C; 1H-NMR (DMSO-d6, 600 MHz) δ 9.91 (s, 1 H), 8.29 (bs, 1 H), 7.83 (s, 1 H), 
3.25–3.20 (m, 4 H), 2.04–1.99 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 160.8, 147.2, 145.7, 145.1, 
125.1, 123.4, 123.1, 114.8, 111.7, 40.1, 26.9, 26.1; IR (ATR, neat) 3377, 3077 (br), 2969, 1643, 1568, 
1428, 1327, 1233, 1171 cm–1; HRMS (ESI) m/z calcd for C12H9Cl2NO3 ([M+Na]+), 307.9857, found 
307.9882. 
6-Allyl-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-02). Yield: 87%; 
m.p. 255–257 °C; IR (ATR, neat) 3174 (br), 3056, 2920, 1641, 1571, 1476, 1426, 1358, 1343, 1272, 
1118 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.19 (s, 1 H), 8.12 (t, 1 H, J = 4.8 Hz), 7.28 (d, 1 H,  
J = 9.0 Hz), 6.98 (d, 1 H, J = 9.0 Hz), 6.00 (ddt, 1 H, J = 17.4, 10.2, 5.4 Hz,), 4.97 (dd, 1 H, J = 10.2,  
1.2 Hz), 4.79 (dd, 1 H, J = 17.4, 1.2 Hz), 3.64 (d, 2 H, J = 5.4 Hz), 3.20 (dd, 2 H, J = 9.0, 5.4 Hz), 3.14 
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(t, 2 H, J = 6.6 Hz), 2.02–1.95 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 161.6, 150.9, 148.1, 143.8, 
137.5, 127.5, 124.0, 118.4, 116.1, 114.8, 109.7, 40.3, 29.1, 27.3, 25.9; HRMS (ESI) m/z calcd for 
C15H15NO3 ([M+Na]+), 280.0950, found 280.0960. 
 
6-[(E)-2-(Prop-1-enyl)]-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB96-
30). Yield: 37%; m.p. >300 °C; IR (ATR, neat) 3147 (br), 2908, 1644, 1568, 1477, 1417, 1245,  
1165 cm–1; 1H-NMR (CD3OD, 600 MHz) δ 7.23 (d, 1 H, J = 9.0 Hz), 6.97 (d, 1 H, J = 9.0 Hz), 6.69 
(dd, 1 H, J = 15.6, 1.2 Hz), 6.22 (dq, 1 H, J = 15.6, 6.6 Hz), 3.40–3.37 (m, 2 H), 3.15 (t, 2 H,  
J = 6.6 Hz), 2.15–2.10 (m, 2 H), 1.95 (dd, 3 H, J = 6.6, 1.8 Hz); 13C-NMR (CD3OD, 150 MHz) δ 
165.2, 152.0, 150.5, 144.4, 133.8, 128.0, 127.9, 124.8, 120.7, 118.2, 111.0, 42.4, 29.5, 28.3, 19.3; 
HRMS (ESI) m/z calcd for C15H15NO3 ([M+Na]+) 280.0950, found 280.0950. 
7-Hydroxy-3,4-dihydro-[1]benzoxolo[2,3-c]azepine-1,5(2H)-dione (kb-NB123-63). Yield: 38%; m.p. 
>300 °C; IR (ATR, neat) 3189 (br), 3072, 2919, 1674, 1645, 1544, 1461, 1349, 1262, 1223 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 8.87 (t, 1 H, J = 4.8 Hz), 7.58 (d, 1 H, J = 9.0 Hz), 7.57 (d, 1 H,  
J = 2.4 Hz), 6.97 (dd, 1 H, J = 9.0, 2.4 Hz), 3.51–3.46 (m, 2 H), 2.93–2.87 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 195.7, 159.8, 155.4, 151.3, 147.9, 125.5, 119.1, 117.1, 112.5, 107.2, 44.1, 
36.0; HRMS (EI) m/z calcd for C12H9NO4 (M+) 231.0532, found 231.0530. 
5,7-Dihydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB123-89). Yield: 79%; m.p. 
280–282 °C; IR (ATR, neat) 3189 (br), 3074, 2918, 1646, 1577, 1455, 1436, 1337, 1178 cm–1; 1H-
NMR (CD3OD, 600 MHz) δ 7.39 (d, 1 H, J = 9.0 Hz), 7.23 (d, 1 H, J = 2.4 Hz), 6.97 (dd, 1 H,  
J = 9.0, 2.4 Hz), 5.14 (d, 1 H, J = 4.2 Hz), 3.58 (dd, 1 H, J = 15.0, 10.2 Hz), 3.37–3.32 (m, 1 H),  
2.32–2.26 (m, 1 H), 2.21–2.14 (m, 1 H); 13C-NMR (CD3OD, 150 MHz) δ 164.4, 155.0, 150.4, 144.2, 
130.1, 127.5, 118.2, 113.0, 107.3, 64.6, 37.3, 37.1; HRMS (EI) m/z calcd for C12H11NO4 (M+) 
233.0688, found 233.0691. 
7-Hydroxy-5-(2-phenylhydrazono)-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB142-
05). Yield: 13%; m.p. 234–236 °C; IR (ATR, neat) 3218 (br), 2924, 1643, 1600, 1553, 1447, 1341, 
1250, 1144 cm–1; 1H-NMR (CD3OD, 600 MHz) δ 7.93 (d, 1 H, J = 2.4 Hz), 7.41 (d, 1 H, J = 8.4 Hz), 
7.34–7.27 (m, 4 H), 7.01 (dd, 1 H, J = 9, 2.4 Hz), 6.87 (tt, 1 H, J = 6.0, 1.2 Hz), 3.60–3.57 (m, 2 H), 
3.00–2.97 (m, 2 H); 13C-NMR (CD3OD, 150 MHz) δ 165.7, 155.4, 150.8, 146.8, 144.6, 139.2, 130.2 (2 
C), 127.5, 124.8, 121.3, 118.1, 114.5 (2 C), 112.8, 110.6, 39.0, 32.4; HRMS (EI) m/z calcd for 
C18H15N3O3 (M+) 321.1113, found 321.1110. 
7-Hydroxy-5-[2-{(4-methylphenyl)sulfony}hydrazono]-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-
1-one (kb-NB142-11). Yield: 46%; m.p. 220–224 °C; IR (ATR, neat) 3212 (br), 1648, 1559, 1448, 
1334, 1161 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 10.69 (s, 1 H), 9.53 (s, 1 H), 8.48 (bs, 1 H), 7.91 
(d, 2 H, J = 7.2 Hz), 7.55 (s, 1 H), 7.45 (d, 1 H, J = 9.0 Hz), 7.35 (d, 2 H, J = 7.80 Hz), 6.94 (d, 1 H,  
J = 8.4 Hz), 3.33–3.28 (m, 2 H), 2.76–2.83 (m, 2 H), 2.33 (s, 3 H); 13C-NMR (CD3OD, 150 MHz) δ 
164.6, 155.8, 151.2, 150.6, 147.0, 145.6, 137.3, 130.6 (2 C), 129.2 (2 C), 127.0, 122.3, 118.3, 112.7, 
110.8, 38.6, 32.9, 21.5; HRMS (EI) m/z calcd for C19H17N3O5S (M+), 422.0787, found 422.0817. 
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5-(Benzyloxyimino)-7-hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]azepin-1-one (kb-NB142-10). 
Yield: 74%; m.p. 103–110 °C; IR (ATR, neat) 3217 (br), 2925, 1648, 1552, 1467, 1448, 1351, 1334, 
1209, 1185 cm–1; 1H-NMR (CD3OD, 600 MHz) δ 7.66 (t, 1 H, J = 1.8 Hz), 7.47 (dd, 2 H, J = 7.8,  
0.6 Hz), 7.41 (dd, 1 H, J = 9.0, 1.2 Hz), 7.37 (dt, 2 H, J = 7.8, 7.2 Hz), 7.31 (td, 1 H, J = 7.2, 0.6 Hz), 
6.98 (ddd, 1 H, J = 9, 2.4, 1.8 Hz), 5.33 (s, 2 H), 3.45–3.42 (m, 2 H), 3.11–3.07 (m, 2 H); 13C-NMR 
(CD3OD, 150 MHz) δ 164.7, 155.7, 153.7, 150.7, 146.9, 139.0, 129.5 (2 C), 129.5 (2 C), 129.1, 126.8, 
120.7, 118.3, 112.9, 110.7, 78.1, 38.7, 31.2. 
 
2,3,4,9-Tetrahydro-6-hydroxy-1H-pyrido[3,4-b]indol-1-one (kb-NB123-59) [63]. Yield: 95%; m.p. 
244–247 °C; IR (ATR, neat) 3391, 3267, 1650, 1618, 1498, 1335, 1207 cm–1; 1H-NMR (DMSO-d6, 
600 MHz) δ 11.26 (s, 1 H), 8.85 (d, 1 H, J = 2.4 Hz), 7.47 (s, 1 H), 7.18 (dd, 1 H, J = 8.4, 3.0 Hz), 6.83 
(d, 1 H, J = 2.4 Hz), 6.74 (dd, 1 H, J = 8.4, 2.4 Hz), 3.50–3.43 (m, 2 H), 2.84–2.79 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 162.0, 150.9, 131.8, 127.5, 125.5, 117.1, 115.1, 113.0, 103.0, 41.2, 20.4; 
HRMS (EI) m/z calcd for C11H10N2O2 (M+) 202.0742, found 202.0752.  
3,4,5,10-Tetrahydro-7-hydroxy-azepino[3,4-b]indol-1(2H)-one (kb-NB123-57). Yield: 89%; IR (ATR, 
neat) 3362, 3276, 1600, 1545, 1484, 1362 cm–1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.82 (s,  
1 H), 8.78 (s, 1 H), 7.86 (t, 1 H, J = 4.5 Hz), 7.19 (d, 1 H, J = 8.7 Hz), 6.79 (d, 1 H, J = 1.8 Hz), 6.73 
(dd, 1 H, J = 8.7, 2.3 Hz), 3.30–3.22 (m, 2 H), 2.91 (t, 2 H, J = 6.3 Hz), 2.07–1.94 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 164.2, 150.6, 130.5, 128.1, 127.6, 115.7, 115.2, 112.7, 102.8, 41.6, 26.9, 25.4; 
HRMS (EI) m/z calcd for C12H12N2O2 (M+) 216.0899, found 216.0898. 
2,3,4,9-Tetrahydro-6-benzyloxy-1H-pyrido[3,4-b]indol-1-one (kb-NB123-52) [63]. Yield: 52%; m.p. 
208–210 °C; IR (ATR, neat) 3233, 2905, 2691, 1567, 1508, 1379, 1242 cm–1; 1H-NMR (DMSO-d6, 
600 MHz) δ 11.45 (s, 1 H), 7.53 (s, 1 H), 7.47 (d, 2 H, J = 7.2 Hz), 7.39 (t, 2 H, J = 7.8 Hz), 7.32 (t,  
1 H, J = 7.2 Hz), 7.29 (d, 1 H, J = 9.0 Hz), 7.17 (d, 1 H, J = 1.8 Hz), 6.94 (dd, 1 H, J = 9.0, 1.8 Hz), 
5.10 (s, 2 H), 3.48 (td, 2 H, J = 6.6, 1.8 Hz), 2.87 (t, 2 H, J = 6.6 Hz); 13C-NMR (DMSO-d6, 150 MHz) 
δ 161.9, 152.6, 137.6, 132.5, 128.4 (2 C), 127.8, 127.7 (2 C), 127.7, 125.1, 117.7, 115.6, 113.4, 102.4, 
69.7, 41.2, 20.5; HRMS (EI) m/z calcd for C18H16N2O2 (M+) 292.1212, found 292.1223. 
3,4,5,10-Tetrahydro-7-benzyloxy-azepino[3,4-b]indol-1(2H)-one (kb-NB123-53). Yield: 53%; 
representative experimental data: IR (ATR, neat) 3227, 3194, 3033, 2920, 1623, 1543, 1478, 1453, 
1276, 1197 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 11.03 (s, 1 H), 7.95 (bs, 1 H), 7.50–7.42 (d, 2 H), 
7.41–7.33 (m, 2 H), 7.32–7.29 (m, 2 H), 7.11 (bs, 1 H), 6.97–6.91 (m, 1 H), 5.10 (s, 2 H), 3.38–3.34 
(m, 2 H), 2.96 (bs, 2 H), 2.02 (bs, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 164.1, 152.3, 137.6, 131.3, 
128.4, 127.8, 127.7, 127.6, 116.4, 115.6, 113.0, 102.2, 69.7, 41.6, 26.8, 25.4; HRMS (EI) m/z calcd for 
C19H18N2O2 (M+) 306.1368, found 306.1366.  
6-Amino-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (kb-NB142-08). Yield: 69%; m.p.  
280–282 °C (lit. 280–282 °C) [65]; IR (ATR, neat) 3356, 3230, 1653, 1501, 1327, 1225 cm–1; 1H-
NMR (CD3OD, 600 MHz) δ 7.25 (d, 1 H, J = 8.4 Hz), 6.93 (s, 1 H), 6.86 (d, 1 H, J = 8.4 Hz), 3.62 (t, 
2 H, J = 7.2 Hz), 2.94 (t, 2 H, J = 7.2 Hz); 13C-NMR (CD3OD, 150 MHz) δ 165.2, 141.1, 134.4, 127.6, 
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127.2, 120.0, 118.5, 113.9, 105.9, 42.8, 21.6; HRMS (EI) m/z calcd for C11H11N3O (M+) 201.0902, 
found 201.0901. 
6-Amino-3,4,5,10-tetrahydro-1H-azepino[3,4-b]indol-1(2H)-one (kb-NB142-01). Yield: 68% m.p. 
202–207 °C; IR (ATR, neat) 3208, 2921, 1618, 1542, 1479, 1450, 1335, 1296 cm–1; 1H-NMR (DMSO-
d6, 600 MHz) δ 10.85 (s, 1 H), 7.93–7.85 (m, 1 H), 7.22–7.17 (m, 1 H), 6.86–6.83 (m, 1 H), 6.78–6.74 
(m, 1 H), 6.39 (bs, 2 H), 3.30–3.24 (m, 2 H), 2.94–2.88 (m, 2 H), 2.04–1.98 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 164.3, 140.7, 130.0, 128.3, 127.0, 115.8, 115.1, 112.4, 101.9, 41.6, 27.0, 25.5; 
HRMS (EI) m/z calcd for C12H13N3O (M+) 215.1059, found 215.1062. 
N-(2,3,4,9-Tetrahydro-1-oxo-1H-pyrido[3,4-b]indol-6-yl)-acetamide (kb-NB123-93). Yield: 24%; 
m.p. >300 °C (lit > 320 °C) [65]; IR (ATR, neat) 3206, 1642, 1588, 1542, 1484, 1437, 1270 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 11.50 (s, 1 H), 9.80 (s, 1 H), 7.91 (s, 1 H), 7.54 (s, 1 H), 7.32–7.22 (m, 
2 H), 3.52–3.45 (m, 2 H), 2.89–2.83 (m, 2 H), 2.03 (s, 3 H); 13C-NMR (DMSO-d6, 150 MHz) δ 167.8, 
161.8, 133.8, 131.9, 127.8, 124.6, 118.0, 117.9, 112.4, 109.8, 41.1, 23.9, 20.4; HRMS (EI) m/z calcd 
for C13H13N3O2 (M+) 243.1008, found 243.1009.  
N-(3,4,5,10)-Tetrahydro-1-oxo-1H-azepino[3,4-b]indol-7-yl)-(2H)-acetamide (kb-NB123-94). Yield: 
75%; m.p. > 300 °C; IR (ATR, neat) 3270, 1618, 1547, 1477, 1453, 1267 cm–1; 1H-NMR (DMSO-d6, 
600 MHz) δ 11.06 (s, 1 H), 9.80 (s, 1 H), 7.95 (t, 1 H, J = 4.5 Hz), 7.88 (s, 1 H), 7.32–7.25 (m, 2 H), 
3.30–3.26 (m, 2 H), 2.95 (t, J = 6.6 Hz, 2 H), 2.00–2.06 (m, 5 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
167.7, 164.1, 132.6, 131.5, 127.8, 127.2, 118.1, 116.6, 112.0, 109.7, 41.5, 26.9, 25.4, 23.9; HRMS (EI) 
m/z calcd for C14H15N3O2 (M+) 257.1164, found 257.1166. 
3,4-Dihydro-9-benzyloxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB123-66). Yield: 87%; 
representative experimental data: m.p. 247–249 °C; IR (ATR, neat) 3165, 3037, 1650, 1500,  
1282 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 8.47 (t, 1 H, J = 5.6 Hz), 7.90 (d, 1 H, J = 8.8 Hz), 7.49 
(d, 2 H, J = 7.5 Hz), 7.40 (t, 2 H, J = 7.7 Hz), 7.36–7.32 (m, 1 H), 7.29–7.27 (m, 1 H), 7.26–7.23 (m,  
1 H), 5.20 (s, 2 H), 3.64–3.60 (m, 2 H), 3.41–3.37 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 165.1, 
156.4, 139.4, 136.9, 133.3, 131.2, 128.5, 127.9, 127.8, 123.8, 118.0, 105.8, 69.6, 42.4, 33.4; HRMS 
(EI) m/z calcd for C18H15NO2S2 (M+) 341.0544, found 341.0543. 
3,4-Dihydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB142-70). Yield: 93%; 
representative experimental data: m.p. 218–220 °C (dec., dark brown), 235–238 °C (dec.); IR (ATR, 
neat) 3269, 1633, 1597, 1496, 1432, 1197 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.73 (s, 1 H), 8.42 
(t, 1 H, J = 5.5 Hz), 7.77 (d, 1 H, J = 8.7 Hz), 7.11 (d, 1 H, J = 1.9 Hz), 7.01 (dd, 1 H, J = 8.7, 1.6 Hz), 
3.64–3.59 (m, 2 H), 3.40–3.36 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 165.2, 155.3, 139.6, 132.8, 
129.3, 127.l, 123.6, 117.8, 107.0, 42.5, 33.3; HRMS (EI) m/z calcd for C11H9NO2S2 (M+) 251.0075, 
found 251.0080. 
3,4-Dihydro-9-methoxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB165-09) [68]. Yield: 
92%; m.p. 202–204 °C (lit. 209–209.5 °C) [78]; IR (ATR, neat) 3156, 3018, 2916, 1633, 1499, 1403, 
1284 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 8.47 (t, 1 H, J = 5.3 Hz), 7.89 (d, 1 H, J = 8.3 Hz),  
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7.19–7.15 (m, 2 H), 3.84 (s, 3 H), 3.65–3.60 (m, 2 H), 3.42–3.38 (m, 2 H); 13C-NMR (DMSO-d6,  
150 MHz) δ 165.2, 157.4, 139.4, 133.4, 130.9, 127.7, 123.8, 117.5, 104.4, 55.4, 42.4, 33.4; HRMS (EI) 
m/z calcd for C12H11NO2S2 (M+) 265.0231, found 265.0232. 
3,4-Dihydro-9-amino-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (mcf292-03). Yield: 71%; m.p. 
198.6–199.0 °C; IR (ATR, neat) 3370, 3254, 3146, 3008, 2915, 1623, 1599, 1556, 1491, 1454, 1430, 
1403, 1346, 1333, 1312, 1286, 1243, 1204, 1184, 1129, 1083, 975, 887, 837, 798, 766, 749, 719, 691, 
677, 663 cm–1; 1H-NMR (CD3OD, 400 MHz) δ 7.58 (dd, 1 H, J = 8.8, 0.4 Hz), 7.15 (dd, 1 H, J = 2.4, 
0.4 Hz), 6.98 (dd, 1 H, J = 8.8, 2.0 Hz), 3.77–3.71 (m, 2 H), 3.42–3.37 (m, 2 H); 13C-NMR (CD3OD, 
100 MHz) δ 169.3, 147.0, 141.5, 132.4, 130.8, 130.7, 124.0, 119.7, 108.4, 44.3, 35.1; MS (EI) m/z 250 
(M+, 100); HRMS (EI) m/z calcd for C11H10N2OS2 (M+) 250.0235, found 250.0225. 
3,4-Dihydro-9-azido-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (mcf292-08). Yield: 53%, 96% 
purity estimated by 1H-NMR; m.p. 193 °C (dec.); IR (ATR, neat) 3260, 3154, 3016, 2922, 2115, 1631, 
1592, 1495, 1467, 1441, 1422, 1400, 1340, 1284, 1252, 1234, 1215, 1198, 1144, 1113, 975, 889, 835, 
809, 792, 751, 721 cm–1; 1H-NMR (DMSO-d6, 400 MHz) δ 8.53 (bt, 1 H, J = 5.6 Hz), 8.06 (d, 1 H,  
J = 8.8 Hz), 7.39 (d, 1 H, J = 1.6 Hz), 7.31 (dd, 1 H, J = 8.6, 2.2 Hz), 3.68–3.60 (m, 2 H), 3.45–3.38 
(m, 2 H); 13C-NMR (DMSO-d6, 100 MHz) δ 164.9, 139.4, 136.9, 135.2, 134.2, 127.7, 124.6, 119.2, 
112.0, 42.4, 33.4; MS (EI) m/z 276 (M+, 14), 248 ([M–N2]+, 50), 68 (100); HRMS (EI) m/z calcd for 
C11H8N4OS2 (M+) 276.0140, found 276.0137. 
3,4-Dihydro-9-isothiocyanato-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (mcf292-05). Yield: 
58%, 98% purity estimated by 1H-NMR; m.p. 253.0–253.3 °C (softening point: 251.6 °C); IR (ATR, 
neat) 3260, 3155, 3025, 2922, 2067 (broad), 1633, 1590, 1497, 1469, 1457, 1441, 1420, 1400, 1340, 
1321, 1282, 1254, 1241, 1141, 941, 900, 852, 807, 792, 744 cm–1; 1H-NMR (DMSO-d6, 400 MHz) δ 
8.56 (bt, 1 H, J = 5.8 Hz), 8.11 (dd, 1 H, J = 8.8, 0.4 Hz), 7.80 (dd, 1 H, J = 2.0, 0.4 Hz), 7.58 (dd, 1 H, 
J = 8.8, 2.0 Hz), 3.68–3.61 (m, 2 H), 3.46–3.39 (m, 2 H); 13C-NMR (DMSO-d6, 100 MHz) δ 164.7, 
139.0, 137.7, 134.4, 128.2, 127.2, 124.9, 124.5, 119.7, 42.4, 33.3; MS (EI) m/z 292 (M+, 47), 113 (57), 
95 (86), 83 (96), 81 (100); HRMS (EI) m/z calcd for C12H8N2OS3 (M+) 291.9799, found 291.9795.  
3,4-Dihydro-9-(2-chloroacetamido)-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (mcf292-09). 
Yield: 65%; m.p. 229–230 °C (dec.); IR (ATR, neat) 3381, 3262, 3155, 3010, 2928, 1668, 1649, 1635, 
1571, 1523, 1495, 1467, 1446, 1403, 1338, 1277, 1266, 1243, 1187, 1144, 986, 891, 876, 816, 790, 
773, 734, 729 cm–1; 1H-NMR (DMSO-d6, 300 MHz) δ 8.48 (bt, 1 H, J = 5.8 Hz), 8.25 (d, 1 H,  
J = 1.5 Hz), 7.95 (d, 1 H, J = 8.7 Hz), 7.63 (dd, 1 H, J = 8.7, 2.1 Hz), 4.29 (s, 2 H), 3.70–3.58 (m, 2 H), 
3.45–3.38 (m, 2 H); 13C-NMR (DMSO-d6, 100 MHz) δ 165.0, 164.8, 138.7, 135.9, 133.7, 132.9, 
128.2, 123.2, 119.8, 112.4, 43.6, 42.5, 33.2; MS (EI) m/z 328 (40), 326 (M+, 100); HRMS (EI) m/z 
calcd for C13H11ClN2O2S2 (M+) 325.9950, found 325.9952. 
3,4-Dihydro-9-hydroxy-10-iodo-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB165-31). 
Yield: 66%; m.p. 128 °C (dec.); IR (ATR, neat) 3335, 3071 (br), 1595, 1485, 1387, 1292 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 10.52 (s, 1 H), 8.54 (t, 1 H, J = 5.4 Hz), 7.80 (d, 1 H, J = 8.4 Hz), 7.11 
(d, 1 H, J = 8.4 Hz), 3.47 (q, 2 H, J = 5.4 Hz), 3.30–3.26 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
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165.1, 155.2, 138.6, 138.3, 132.0, 128.7, 123.9, 115.4, 78.7, 42.2, 35.5; HRMS (EI) m/z calcd for 
C11H8INO2S2 (M+) 376.9041, found 376.9045. 
 
3,4-Dihydro-9-hydroxy-10-bromo-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-52). 
Yield: 25%; m.p. 235–238 °C (dec., brown); IR (ATR, neat) 3350, 3083, 2918, 1595 1492, 1396,  
1303 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 10.38 (s, 1 H), 8.52 (t, 1 H, J = 5.4 Hz), 7.78 (d, 1 H,  
J = 8.4 Hz), 7.16 (d, 1 H, J = 8.4 Hz), 3.53 (q, 2 H, J = 5.4 Hz), 3.31–3.27 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 164.8, 152.6, 136.5, 136.4, 132.0, 129.1, 122.8, 117.1, 103.3, 42.6, 34.8; 
HRMS (EI) m/z calcd for C11H8BrNO2S2 (M+) 328.9149 found 328.9164. 
3,4-Dihydro-7-benzyloxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-38). Yield: 53%; 
m.p. 213–215 °C; IR (ATR, neat) 3159, 3036, 2923, 1647, 1462, 1257 cm–1; 1H-NMR (DMSO-d6,  
600 MHz) δ 8.47 (t, 1 H, J = 5.4 Hz), 7.49 (d, 2 H, J = 7.2 Hz), 7.22–7.31 (m, 5 H), 7.19 (d, 1 H,  
J = 3.0 Hz), 5.35 (s, 2 H), 3.68–3.62 (m, 2 H), 3.42–3.38 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
165.0, 152.7, 140.0, 136.6, 132.1, 129.0, 128.6 (2 C), 128.0, 127.9, 127.4 (2 C), 126.6, 115.4, 108.7, 
69.7, 42.6, 33.1; HRMS (EI) m/z calcd for C18H15NO2S2 (M+) 341.0544, found 341.0543. 
3,4-Dihydro-7-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-40). Yield: 73%; 
m.p. 269–272 °C (dec., dark brown), 278–281 °C (dec.); IR (ATR, neat) 3255, 3155, 3015, 1620, 
1439, 1285 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1 H), 8.45 (t, 1 H, J = 5.4 Hz), 7.29 (t, 1 
H, J = 7.8 Hz), 7.24 (d, 1 H, J = 7.9 Hz), 6.89 (d, 1 H, J = 7.5 Hz), 3.65–3.60 (m, 2 H), 3.40–3.36 (m, 2 
H); 13C-NMR (DMSO-d6, 150 MHz) δ 165.2, 152.1, 140.3, 131.8, 128.8, 126.65, 126.61, 113.7, 110.8, 
42.5, 33.2; HRMS (EI) m/z calcd for C11H9NO2S2 (M+) 251.0075, found 251.0066. 
3,4-Dihydro-7-methoxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-44). Yield: 99%; 
m.p. 220–224 °C; IR (ATR, neat) 3163, 3032, 2932, 1634, 1467, 1261 cm–1; 1H-NMR (DMSO-d6,  
600 MHz) δ 8.48 (t, 1 H, J = 4.8 Hz), 7.44 (t, 1 H, J = 7.8 Hz), 7.37 (d, 1 H, J = 7.8 Hz), 7.09 (d, 1 H,  
J = 7.8 Hz), 3.96 (s, 3 H), 3.66–3.61 (m, 2 H), 3.42–3.37 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
165.0, 153.8, 139.9, 132.0, 128.9, 127.4, 126.7, 115.1, 107.2, 55.9, 42.5, 33.1; HRMS (ESI) m/z calcd 
for C12H11NO2S2 ([M+Na]+) 288.0129, found 288.0102. 
3,4-Dihydro-9-hydroxy-6-oxide-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-22). 
Yield: 80%; m.p. 160–163 °C (dec., brown) 280–282 °C (dec., melts); IR (ATR, neat) 3369 (br), 1648, 
1608, 1577, 1452, 1335, 1245, 998 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.90 (bs, 1 H), 7.80 (bs,  
1 H), 7.47 (s, 1 H), 7.33 (d, 1 H, J = 9.0 Hz), 7.04 (d, 1 H, J = 9.0 Hz), 3.73–3.63 (m, 2 H), 3.00–2.90 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 175.8, 156.2, 146.6, 127.3, 123.5, 121.7, 118.1, 109.5, 
101.7, 42.6, 22.7; MS (ESI) m/z 268 ([M+H]+). 
3,4-Dihydro-9-methoxy-6-oxide-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-25).Yield: 
58%; m.p. 284–287 °C; IR (ATR, neat) 3340, 1506, 1477, 1337, 1248 cm–1; 1H-NMR (DMSO-d6,  
600 MHz) δ 7.93 (bs, 1 H), 7.60 (d, 1 H, J = 2.4 Hz), 7.46 (d, 1 H, J = 9.0 Hz), 7.18 (dd, 1 H, J = 9.0, 
2.4 Hz), 3.86 (s, 3 H), 3.75–3.69 (m, 2 H), 3.00–2.95 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
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175.7, 158.1, 146.5, 127.5, 123.7, 123.2, 117.3, 107.4, 102.0, 55.8, 42.6, 22.7; MS (ESI) m/z 282 
([M+H]+); HRMS (EI) m/z calcd for C12H11NO3S2 (M+) 281.0180, found 281.0180. 
3,4-Dihydro-9-methoxy-1-oxide-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB184-45).Yield: 
54%; m.p. 215–217 °C; IR (ATR, neat) 3156, 3020, 2915, 1638, 1507 cm–1; 1H-NMR (DMSO-d6,  
600 MHz) δ 8.99 (bs, 1 H), 8.03 (d, 1 H, J = 9.0 Hz), 7.59 (d, 1 H, J = 2.4 Hz), 7.25 (dd, 1 H, J = 8.4, 
2.4 Hz), 3.94–3.87 (m, 1 H), 3.87 (s, 3 H), 3.59–3.51 (m, 3 H); 13C-NMR (DMSO-d6, 150 MHz) δ 
162.4, 157.8, 141.9, 140.1, 133.6, 131.5, 124.0, 117.9, 104.6, 55.5, 50.4, 32.6; HRMS (EI) m/z calcd 
for C12H11NO3S2 (M+) 281.0180, found 281.0177. 
2,3,4,5-Tetrahydro-10-benzyloxybenzo[b]thieno[2,3-f]-1,5-thiazocin-6-one (kb-NB165-89). Yield: 
42%; m.p. 198–199 °C; IR (ATR, neat) 3162, 3033, 2937, 1644, 1619, 1600, 1497, 1384, 1274,  
1193 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 8.02 (bs, 1 H), 7.90–7.84 (m, 1 H), 7.51–7.45 (m, 2 H), 
7.43–7.37 (m, 2 H), 7.36–7.31 (m, 1 H), 7.26–7.19 (m, 2 H), 5.20 (s, 2 H), 3.50–3.43 (m, 2 H),  
3.30–3.24 (m, 2 H), 1.92–1.89 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 164.8, 156.4, 138.7, 136.9, 
130.3, 128.5, 128.5, 127.9, 127.7, 127.4, 123.6, 117.3, 105.8, 69.6, 30.5, 27.4; MS (EI) m/z 356 (23), 
355 (M+, 100), 357 (12); HRMS (EI) m/z calcd for C19H17NO2S2 (M+) 355.0701, found 355.0689. 
2,3,4,5-Tetrahydro-10-hydroxybenzo[b]thieno[2,3-f]-1,5-thiazocin-6-one (kb-NB165-92). Yield: 
92%; m.p. 139–142 °C; IR (ATR, neat) 3256 (br), 3169 (br), 1615, 1492, 1444, 1182 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 9.71 (s, 1 H), 7.97 (t, 1 H, J = 7.8 Hz), 7.74 (d, 1 H, J = 8.6 Hz), 7.09 (s, 1 H), 
6.98 (d, 1 H, J = 8.6 Hz), 3.50–3.43 (m, 2 H), 3.30–3.23 (m, 2 H), 1.92–1.85 (m, 2 H); 13C-NMR 
(DMSO-d6, 150 MHz) δ 164.9, 155.3, 139.0, 128.4, 127.0, 123.4, 117.1, 106.8, 30.5, 27.3; MS (EI) 
m/z 266 (15), 265 (M+, 100), 267 (11); HRMS (EI) m/z calcd for C12H11NO2S2 (M+) 265.0231, found 
265.0230. 
2,3,4,5-Tetrahydro-10-methoxybenzo[b]thieno[2,3-f]-1,5-thiazocin-6-one (kb-NB184-02). Yield: 
77%; m.p. 185–188 °C; IR (ATR, neat) 3152, 3026, 2939, 1636, 1498, 1395, 1209 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 8.02 (t, 1 H, J = 7.1 Hz), 7.87 (d, 1 H, J = 9.4 Hz), 7.16–7.13 (m, 2 H), 3.84 
(s, 3 H), 3.50–3.44 (m, 2 H), 3.30–3.26 (m, 2 H), 1.92–1.87 (m, 2 H); 13C-NMR (DMSO-d6,  
150 MHz) δ 164.8, 157.4, 138.7, 130.1, 127.4, 123.6, 116.8, 104.3, 55.4, 30.5, 27.4; MS (EI) m/z 280 
(16), 279 (M+, 100); HRMS (EI) m/z calcd for C13H13NO2S2 (M+) 279.0388, found 279.0379. 
2,3,4,5-Tetrahydro-10-benzyloxybenzo[b]thieno[2,3-f]-1,5-oxazocin-6-one (kb-NB184-36). Yield: 
51%; m.p. 195–200 °C; IR (ATR, neat) 2912 (br), 2298, 1637, 1607, 1528, 1455, 1422 1222 cm–1; 1H-
NMR (DMSO-d6, 600 MHz) δ 8.00 (t, 1 H, J = 7.2 Hz), 7.75 (d, 1 H, J = 8.4 Hz), 7.47 (d, 2 H,  
J = 7.8 Hz), 7.40 (t, 2 H, J = 7.8 Hz), 7.37–7.32 (m, 1 H), 7.26 (d, 1 H, J = 2.4 Hz), 7.18 (dd, 1 H,  
J = 8.4, 2.4 Hz), 5.17 (s, 2 H), 4.49 (t, 2 H, J = 5.4 Hz), 3.40–3.35 (m, 2 H), 1.87 (quint, 2 H,  
J = 5.4 Hz); 13C-NMR (DMSO-d6, 150 MHz) δ 165.1, 156.2, 149.2, 137.0, 133.5, 129.2, 128.5 (2 C), 
127.9, 127.6 (2 C), 123.8, 118.3, 112.0, 104.7, 69.5, 68.6, 37.8, 29.2; HRMS (ESI) m/z calcd for 
C19H17NO3S ([M+Na]+) 362.0827, found 362.0809. 
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2,3,4,5-Tetrahydro-10-methoxybenzo[b]thieno[2,3-f]-1,5-oxazocin-6-one (kb-NB184-57). Yield: 
35%; m.p. 233–237 °C; IR (ATR, neat) 3154, 3027, 2919, 1631, 1467, 1422, 1220 cm–1; 1H-NMR 
(DMSO-d6, 600 MHz) δ 8.00 (t, 1 H, J = 6.6 Hz), 7.73 (d, 1 H, J = 9.0 Hz), 7.15 (d, 1 H, J = 2.4 Hz), 
7.09 (dd, 1 H, J = 9.0, 2.4 Hz), 4.50 (t, 2 H, J = 5.4 Hz), 3.81 (s, 3 H), 3.42–3.32 (m, 2 H), 1.92–1.84 
(m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 165.1, 157.2, 149.2, 133.5, 128.9, 123.7, 117.9, 112.0, 
103.3, 68.6, 55.3, 37.8, 29.2; HRMS (ESI) m/z calcd for C13H13NO3S ([M+Na]+) 286.0514, found 
286.0510. 
Methyl 3-(3-hydroxypropylamino)-5-methoxybenzo[b]thiophene-2-carboxylate (kb-NB184-80). Yield: 
71%; m.p. 116–120 °C; IR (ATR, neat) 3481, 2921, 1627, 1578, 1440, 1224 cm–1; 1H-NMR (CDCl3, 
600 MHz) δ 7.60 (d, 1 H, J = 8.4 Hz), 7.57 (d, 1 H, J = 2.4 Hz), 7.11 (dd, 1 H, J = 8.4, 2.4 Hz), 3.87 (s, 
3 H), 3.87 (s, 3 H), 3.90–3.87 (m, 2 H), 3.84 (t, 1 H, J = 6.6 Hz), 1.99 (quint, 2 H, J = 6.6 Hz), 1.25 (s, 
2 H); 13C-NMR (CDCl3, 150 MHz) δ 166.4, 157.0, 151.8, 133.3, 133.0, 124.4, 118.1, 107.5, 101.9, 
60.5, 55.8, 51.7, 43.7, 33.6; HRMS (EI) m/z calcd for C14H17NO4S (M+) 295.0878, found 295.0879. 
2,3-Dihydro-4-methyl-9-methoxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB165-16). 
Yield: 71%; m.p. 160–161 °C; IR (ATR, neat) 2928, 1625, 1598, 1497, 1397, 1207 cm–1; 1H-NMR 
(CD3OD, 600 MHz) δ 7.77 (d, 1 H, J = 9.0 Hz), 7.33 (d, 1 H, J = 2.4 Hz), 7.14 (dd, 1 H, J = 9.0,  
2.4 Hz), 3.88 (s, 3 H), 3.86–3.83 (m, 2 H), 3.53–3.50 (m, 2 H), 3.22 (s, 3 H); 13C-NMR (CD3OD,  
150 MHz) δ 167.5, 159.6, 141.3, 136.0, 133.2, 129.2, 124.5, 118.9, 105.7, 56.0, 51.3, 35.8, 35.0; 
HRMS (EI) m/z calcd for C13H13NO2S2 (M+) 279.0388, found 279.0386. 
2,3-Dihydro-4-methyl-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB165-17). 
Yield: 56%; m.p. 265–268 °C; IR (ATR, neat) 3193 (br), 2384, 1610, 1587, 1494, 1401 cm–1; 1H-
NMR (CD3OD, 600 MHz) δ 7.69 (d, 1 H, J = 9.0 Hz), 7.26 (d, 1 H, J = 2.4 Hz), 7.03 (dd, 1 H, J = 9.0,  
2.4 Hz), 3.85 (t, 2 H, J = 5.4 Hz), 3.50 (t, 2 H, J = 5.4 Hz), 3.21 (s, 3 H); 13C-NMR (CD3OD,  
150 MHz) δ 167.6, 156.9, 141.5, 135.5, 131.9, 128.9, 124.4, 118.8, 108.5, 51.4, 35.8, 34.9; HRMS (EI) 
m/z calcd for C12H11NO2S2 (M+) 265.0231, found 265.0235. 
2,3-Dihydro-4-(2-aminoethyl)-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepin-5(2H)-one (kb-NB165-
75). Yield: quant.; m.p. 250–254 °C; IR (ATR, neat) 3251 (br), 2918 (br), 1579, 1500, 1427,  
1178 cm–1; 1H-NMR (DMSO-d6, 600 MHz) δ 9.82 (s, 1 H), 7.99 (bs, 2 H), 7.79 (d, 1 H, J = 9.0 Hz), 
7.18 (d, 1 H, J = 2.4 Hz), 7.04 (dd, 1 H, J = 9.0, 2.4 Hz), 3.85 (t, 2 H, J = 4.8 Hz), 3.73 (t, 2 H,  
J = 6.0 Hz), 3.48 (t, 2 H, J = 4.8 Hz), 3.10–3.03 (m, 2 H); 13C-NMR (DMSO-d6, 150 MHz) δ 165.2, 
155.5, 139.5, 133.6, 129.3, 127.0, 123.7, 117.9, 107.1, 48.3, 45.8, 37.3, 32.8; HRMS (EI) m/z calcd for 
C13H14N2O2S2 (M+) 294.0497, found 294.0492. 
2,3,4,5-Tetrahydro-9-benzyloxy-[1]benzothieno[2,3-f]-1,4-thiazepine (kb-NB165-81). Yield: 15%; 
m.p. 144–145 °C; IR (ATR, neat) 2915, 1596, 1443, 1270, 1192 cm–1; 1H-NMR (CD3OD, 600 MHz) δ 
7.67 (d, J = 9.0 Hz, 1 H), 7.48 (d, 2 H, J = 7.2 Hz), 7.38 (t, 2 H, J = 7.2 Hz), 7.37–7.30 (m, 2 H), 7.06 
(dd, 1 H, J = 9.0, 2.4 Hz), 5.14 (s, 2 H), 4.14 (s, 2 H), 3.44–3.41 (m, 2 H), 2.82–2.79 (m, 2 H); 13C-
NMR (CD3OD, 150 MHz) δ 158.4, 145.0, 142.7, 138.7, 131.3, 129.5 (2 C), 128.9, 128.7 (2 C), 128.0, 
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124.2, 116.5, 107.2, 71.3, 55.3, 35.5; MS (EI) m/z 327 (M+); HRMS (EI) m/z calcd for C18H17NOS2 
(M+) 327.0752, found 327.0749. 
2,3,4,5-Tetrahydro-9-hydroxy-[1]benzothieno[2,3-f]-1,4-thiazepine (kb-NB165-83). Yield: 70%; m.p. 
182–184 °C (dec., dark brown); IR (ATR, neat) 2947 (br), 2920, 1598, 1436, 1183 cm–1; 1H-NMR 
(CD3OD, 600 MHz) δ 7.59 (d, 1 H, J = 9.0 Hz), 7.16 (d, 1 H, J = 2.4 Hz,), 6.88 (dd, 1 H, J = 9.0,  
2.4 Hz), 4.18 (s, 2 H), 3.49–3.45 (m, 2 H), 2.86–2.81 (m, 2 H); 13C-NMR (CD3OD, 150 MHz) δ 156.5, 
143.9, 142.8, 130.1, 127.9, 124.1, 116.1, 108.4, 55.2, 35.1; MS (EI) m/z 238 (14), 237 (M+, 100), 239 
(10); HRMS (EI) m/z calcd for C11H11NOS2 (M+) 237.0282, found 237.0289. 
2-Methoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one (kmg-NB4-23). 
Yield: 68%; m.p. 308 °C (dec.); IR (ATR, neat) 3260, 3153, 3015, 1636, 1554, 1495, 1467, 1374, 
1269, 1353, 1323 cm–1; 1H-NMR (DMSO-d6, 300 MHz) δ 9.36 (s, 1 H), 8.70 (t, 1 H, J = 5.4 Hz), 3.98 
(s, 1 H), 3.68 (app dd, 2 H, J = 6.0 Hz), 3.40–3.36 (m, 2 H); 13C-NMR (DMSO-d6, 75 MHz) δ 164.2, 
163.1, 159.6, 155.9, 138.5, 129.7, 124.1, 54.8, 42.7, 31.9; HRMS (ESI) m/z calcd for C10H10N3O2S2 
([M+H]+) 268.0214, found 268.0237. 
2-Hydroxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one (hydrochloride salt, 
kmg-NB4-69A). Yield: 85%; m.p. 335.9 °C (dec); IR (ATR) cm–1 3452, 3267, 3176, 2591, 2032, 
1912, 1700, 1623, 1463, 1240; 1H-NMR (DMSO-d6, 400 MHz) δ 9.20 (s, 1 H), 8.74 (t, 1 H,  
J = 6.2 Hz), 7.79 (bs, 1 H), 3.68–3.60 (m, 2 H), 3.39–3.32 (m, 2 H); 13C-NMR (DMSO-d6, 100 MHz) δ 
164.0, 161.0, 159.7, 153.6, 140.9, 128.4, 119.6, 42.6, 32.2; HRMS (ESI) m/z calcd for C9H8N3O2S2 
([M+H]+) 254.0058, found 254.0041. 
2,4-Dimethoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one (kmg-NB5-13). 
Yield: 77%; m.p. 288.0 °C (dec); IR (ATR, neat) 3321, 1642, 1579, 1545, 1491, 1476, 1458, 1346, 
1331, 1206 cm–1; 1H-NMR (DMSO-d6, 500 MHz) δ 8.65 (t, 1 H, J = 5.7 Hz), 4.09 (s, 3 H), 3.96 (s,  
3 H), 3.69–3.64 (m, 2 H), 3.38–3.34 (m, 2 H); 13C-NMR (DMSO-d6, 125 MHz) δ 165.5, 164.1, 163.5, 
159.9, 135.9, 130.3, 111.5, 54.74, 54.72, 42.8, 31.8. 
4-Hydroxy-2-methoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one (kmg-
NB5-15). Yield: 77%; m.p. 295.0 °C (dec); IR (ATR, neat) 3266, 3170, 2740, 1674, 1646, 1603, 1465, 
1407, 1316 cm–1; 1H-NMR (DMSO-d6, 400 MHz) δ 12.72 (s, 1 H), 8.56 (t, 1 H, J = 5.2 Hz), 3.94 (s,  
3 H), 3.66–3.60 (m, 2 H), 3.32–3.28 (m, 2 H); 13C-NMR (DMSO-d6, 125 MHz) δ 164.0, 158.4, 156.8, 
153.8, 135.7, 130.6, 118.6, 54.9, 42.7, 31.9; MS (EI) m/z 283 (M+, 100). HRMS (ESI) m/z calcd for 
C10H9N3O3S2Na ([M+Na]+) 305.9983, found 305.9995. 
3.2. IMAP-based kinase counterscreening assay  
An automated, HTS formatted IMAP-based PKD Fluorescence Polarization (FP) assay was used to 
assess the specificity of the PKD analogs as previously described [52]. Briefly, PKD1 kinase reactions 
were assembled by the addition of 3× concentrations of substrate/ATP (300 nm/60 µm), experimental 
compound, and PKD1 enzyme (0.18 milliunits/mL) in a miniaturized reaction volume (i.e., 6 µL). 
Kinase reactions were incubated for 90 min at room temperature and stopped by the addition of IMAP 
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binding reagent. Assay plates were then incubated for 2 h and IMAP-based FP data were captured on a 
Molecular Devices Spectra-Max M5 (Sunnyvale, CA, USA). The IC50 determinations for each 
compound in the PKD1 IMAP FP assay were conducted within the linear range of the captured signal 
readout (n = 3). 
3.3. In vitro radiometric PKD kinase assays 
In vitro radiometric PKD kinase assays were conducted as previously described [52]. Briefly, 50 ng 
recombinant human PKD1 (Biomol International, Plymouth Meeting, PA, USA) was incubated at  
30 °C for 10 min with a reaction mixture containing 2.5 µg syntide-2 (Sigma), 70 µM ATP, and 1 µCi 
γ-
32P-ATP (PerkinElmer, Boston, MA, USA) in kinase buffer (50 mM Tris-HCl pH 7.5, 4 mM MgCl2, 
and 10 mM β-mercaptoethanol). 25 µL of the reaction mixture was then spotted on Whatman P81 filter 
paper (Whatman Inc., Clifton, NJ, USA), and filter papers were washed three times with 0.5% 
phosphoric acid, dried, then counted using a Beckman LS6500 multi-purpose scintillation counter. 
3.4. Determination of cellular IC50 for PKD1 inhibition 
Inhibition of PKD1 in cells was determined by densitometry analysis of Western blotting data for 
PKD1 autophosphorylation at Ser916 in LNCaP cells as previously described [52]. LNCaP cells were 
pre-treated with PKD inhibitors for 45 min at various concentrations, and then stimulated with 10 nM 
phorbol 12-myristate 13-acetate (PMA) for 20 min. Cells were then collected and lysed in lysis buffer 
containing 200 mM Tris-HCl, pH 7.4, 100 µM 4-(2-aminoethyl) benzenesulfonyl fluoride, 1 mM 
EGTA, and 1% Triton X-100. Cell lysates were probed by Western blot analysis using primary 
antibodies targeting p-S916-PKD1 (Millipore), PKD1 (Cell Signaling Technology), or GAPDH. 
Densitometry analysis of visualized bands was used to determine the cellular IC50 values for PKD1 
inhibition. 
3.5. Statistical analysis 
GraphPad Prism V software was used to determine statistical significance. Each assay was repeated 
two or three times with triplicate determination at each point. A p value of < 0.05 was considered 
significant.  
4. Conclusions  
An extensive SAR study starting with the HTS-based confirmed hit CID755673 led to the discovery 
of the benzothienothiazepinone kb-NB142-70 and its methoxy analog kb-NB165-09, which were ca. 
7-fold more potent at PKD1 inhibition. A 4-zone pharmacophore model was developed based on these 
new lead compounds, and systematic modifications of each zone led to a novel series of 
benzothienothiazepinones with equal or greater potencies compared to CID755673. Five of these 
analogs were further investigated, and each of them inhibited PMA-induced autophosphorylation of 
PKD1 [53]. These analogs also caused dramatic arrest in cell proliferation and inhibited cell migration 
and invasion [53]. Furthermore, counterscreens on a panel of other kinases clearly demonstrated a high 
selectivity profile in this series for PKD inhibition [53]. In order to decrease the susceptibility of these 
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compounds to metabolic pathways, a pyrimidine moiety was installed in zone I, leading to a promising 
new lead structure, kmg-NB4-23. Because of the inadequate solubility properties of the pyrimidine-
based inhibitors, additional modifications to zone I are currently being explored in our laboratories. 
Overall, the results of this extensive SAR study suggest that the zone I binding region is restrictive in 
both size and polarity of the aryl substituents. Additionally, it appears that the hydrogen bond donor-
acceptor abilities of the amide moiety are critical for optimal interactions with the zone IV binding site. 
The synthesis of the azide analog mcf292-08 and the electrophilic reactive probe molecules mcf292-05 
and mcf292-09 as tools for photoaffinity/affinity labeling studies was undertaken to gain key structural 
insights into the possible protein binding site. The latter information is currently pending and will be 
utilized for future SAR studies. 
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